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Abstract
Elucidating a Common Mechanism of Proteasome Impairment in Neurodegenerative
Disease and its Pharmacological Intervention
Tiffany Ann Thibaudeau

Proteostasis is maintained by several systems in the cell including the ubiquitin-proteasome
system (UPS), chaperones, chaperone-mediated autophagy, and macroautophagy. The UPS is
the principle route for the degradation of intracellular misfolded, damaged, or unneeded cellular
proteins and has a critical role essential every cell process, including: cell cycle progression,
transcriptional regulation, genome integrity, apoptosis, immune responses, and neuronal
plasticity. When the efficiency of protein degradation is perturbed, misfolded and damaged protein
aggregates can accumulate to toxic levels and cause neuronal dysfunction, which may underlie
many neurodegenerative diseases. It is widely appreciated that soluble oligomers of misfolded
proteins (e.g. Aβ, Alzheimer’s; α-Syn, Parkinson’s; huntingtin with polyglutamine expansion,
Huntington’s) and loss of proteostasis are the key drivers of disease development and
progression. We show that three different proteins from Alzheimer’s, Parkinson’s, and
Huntington’s disease that misfold and oligomerize into a shared three-dimensional structure
potently impair the proteasome. Detailed mechanistic analysis demonstrates that these oligomers
inhibit the 20S proteasome through allosteric impairment of the substrate-gate. To investigate the
feasibility of proteasome gate-activation as a therapeutic strategy, we characterized the
mechanism of proteasome gate activation by the conserved HbYX-motif found in proteasome
activator complexes at the molecular level. Based on these observations, we developed a novel
proteasome gate-activating molecule as a research tool to probe proteasome function in vitro and
in vivo. Together, our results provide a novel molecular model for oligomer-driven proteasome
impairment in neurodegenerative disease and demonstrate the feasibility of designing drug-like
molecules that activate proteasome function patients with neurodegenerative disease.
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Literature Review – Part 1
Neurodegenerative disease and the proteasome
Neurodegenerative disease
Patients with neurodegenerative disease commonly suffer from escalating dementia, memory
loss, and motor impairment as their disease progresses, ultimately resulting in death. The most
common, Alzheimer’s disease (AD), is the fourth leading cause of death in the elderly and a leading cause of poor health and disability1. Deaths due to AD increased by 68% over the past decade.
The annual cost of care for AD is over $250 billion dollars, and is projected to reach $1.2 trillion
by 20501. The devastation caused by the development of AD on the individual and the family unit
is remarkable. Moreover, if left untreated the expected catastrophic impact of AD on our aging
nation has been extensively modeled and discussed 2. These facts clearly highlight the need for
development of therapeutic strategies to combat these costly and deadly diseases.
Compelling evidence from
decades of research indi-

a.

b.

c.

d.

cates that diverse neurodegenerative diseases might
have a common cause and
pathological mechanism protein misfolding, oligomerization, and accumulation,
resulting in loss of proteostasis and neuronal death
The

original

3–5.

amyloid-

Figure 1. Characteristic neurodegenerative disease neuropathological lesions.
(a) AD, neuritic plaque, silver stained (Hirano method)(cerebral cortex). (b) Alzheimer’s disease (AD), neuritic plaque labeled for Aβ (cerebral cortex). (c) Parkinson’s disease (PD), Lewy bodies labeled for α-synuclein (substantial nigra). (d) Huntington’s disease (HD), intranuclear inclusion labeled for huntingtin (cerebral cortex).
Scale bar 50 µm. Figure adapted from [11].
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hypothesis postulated the extracellular, insoluble amyloid-fibrils were responsible for neuron death6. Early
①

treatments focused on ameliorating
pathologies visible with light micros②

copy (e.g. insoluble protein aggregates: amyloid plaques, intracellular
tangles, inclusion bodies) (Figure 1).
However, visible pathology alone

③

does not correlate well with disease7–
10

and clinical trials aimed at prevent-

ing the formation of or removing existing insoluble protein aggregates
Figure 2. Flowchart for pathway of protein aggregation. After initiation
event in protein aggregation, misfolded monomers adopt abnormal conformations and begin to aggregate (1). Oligomeric (globular) intermediates then
form, and protofibrillar structures are assembled (2). Amyloid fibers then
form, resulting in aggregates or inclusions visible in the light microscope (3).
Oligomeric (globular) intermediates are more toxic than the precursor protein
or fibrillar aggregates and inclusions, which may be protective by sequestering the toxic i9ntermediate forms. Figure adapted from [11].

have failed11 (Figure 2). The most
likely explanation is the insoluble aggregates represent an end-stage of

the protein aggregation cascade, and that earlier intermediate steps in the cascade are directly
tied to disease pathogenesis. In this proposed model, the insoluble protein aggregates may be
protective by sequestering the toxic intermediates (Figure 2)12. Culminating evidence from the
past two decades has revealed that soluble, oligomeric forms of protein aggregates (such as Aβ
in Alzheimer’s disease, α-Synuclein in Parkinson’s disease, and mutant huntingtin in Huntington’s
disease) are key players in proteostasis dysfunction13,14. It is now widely appreciated that soluble
oligomers of misfolded proteins (e.g. Aβ, Alzheimer’s; α-Syn, Parkinson’s; huntingtin with polyglutamine expansion, Huntington’s) and loss of proteostasis are the key drivers of disease development and progression15–19.
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Proteostasis and the proteasome
Proteostasis 20,21 is maintained by several systems in the cell including the ubiquitin-proteasome
system (UPS), chaperones, chaperone-mediated autophagy, and macroautophagy22 (Figure 3),
collectively called the Proteostasis Network (PN). If the efficiency of PN declines, misfolded proteins begin to accumulate and aggregate in the cell, which can disrupt normal cellular functions
and even cause cell death23. Maintaining proteostasis is especially important for neurons due to
their complex architecture, long lifespan, and inability to dilute aggregate load by cell division 24.

Figure 3. The Proteostasis Network (PN).
Balanced PN: Components of the PN (chaperones (blue spheres), the UPS, and autophagy) work together to maintain proteins in
their native conformations and eliminate misfolded or metastable intermediates (blue arrows). On-pathway protein folding is highlighted with a blue background (left). The chaperone network (blue spheres) ensures correct folding and trafficking of nascent
proteins. The proteasome degrades over 90% of the proteome, including intrinsically disordered proteins (IDPs) and folded proteins,
and is the principal route for degradation of unneeded, damaged, misfolded or metastable proteins. Cellular stresses (including
mutations, post-translational modifications, and oxidative damage) can partially unfold structured proteins (burgundy arrows). Partially unfolded proteins (and IDPs) can be degraded by the 20S and 26S proteasomes, or self-associate to form aggregates (burgundy arrows). In response to accumulation of misfolded proteins and aggregates, the chaperone network facilitates disaggregation
and refolding of these proteins or directs them to the proteasome for degradation. Large bulk aggregates resistant to disaggregation
are removed by macroautophagy. PN Collapse: When the efficiency of the PN declines, misfolded and metastable proteins accumulate. Protein aggregates cause cellular toxicity, in part through aberrant interactions with cellular proteins, sequestering chaperones, and by impairing the UPS. PN, proteostasis network ; UPS, ubiquitin proteasome system; IDP, intrinsically disordered protein;
E1-3, ubiquitin ligases of the ubiquitination conjugation cascade.
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The UPS is the principle route for the degradation of intracellular misfolded, damaged, or unneeded proteins25. The UPS is critical for normal functioning of neuronal synapses, including synaptic protein turnover, plasticity, and long-term memory formation, all of which rely on tightly controlled changes in the proteome24,26–28. Recently, Ramachandran and Margolis29 identified a specialized neuronal membrane proteasome (NMP) that mediates neuronal function by “inside-out”
signaling through the production of extracellular proteasome-derived peptides. Pharmacological
dissection of the downstream pathways of peptide signaling revealed that NMP-derived peptides
act in part by modulating postsynaptic N-methyl-D-aspartate receptors (NMDARs), and it is wellwell-known that NMDARs are critical for neuronal activity-dependent signaling relevant to learning
and memory30,31.
It is well established that proteasome function is decreased in
neurodegenerative diseases, and
impaired function has been implicated in the development of many
neurodegenerative

diseases,

in-

cluding Alzheimer’s, Parkinson’s,
and

Huntington’s

diseases4,32–35.

Experimental proteasome inhibition

Figure 4. Protein misfolding and proteasome impairment. Neurodegenerative diseases (ND) share the accumulation of toxic protein oligomers
(soluble aggregates). Ubiquitin proteasome system (UPS) impairment is
also a common feature, which can alone lead to neuronal death and NDlike symptoms. Specific toxic oligomer conformations impair proteasome
function, which may be a shared pathological step in early stages of neurodegeneration.

in animals recapitulates many aspects of human neurodegenerative diseases36–39. For example, stereotaxic unilateral infusion of
lactacystin (a selective proteasome inhibitor) into the substantia nigra pars compacta of rats
caused neurodegenerative disease like symptoms40. Several groups have provided evidence that
aggregated proteins from neurodegenerative diseases interact with and impair proteasome 41–49
(Figure 4). We recently identified a mechanism by which neurodegenerative-disease related

4

protein oligomers (Aβ, -synuclein, and mutant huntingtin) impair the proteasome50. Our results
provide a novel molecular model for oligomer-driven impairment of proteasome function that is
relevant to a variety of neurodegenerative diseases.
Increased proteasome activity shown to be beneficial in many related disease models. Drugs that
reverse proteasome impairment in neurodegenerative disease are expected to restore cellular
proteostasis, thereby reducing neuronal loss and simultaneously stimulate clearance of toxic oligomers by depleting the pool of misfolded monomers. Such therapeutic interventions have the
potential to restore proteostasis in patients suffering from neurodegenerative diseases, as evidenced by several recent studies. For example, Choi et al.51 showed that opening of the 20S
proteasome gate (thereby increasing proteasome activity) in cells leads to enhanced cellular proteasome function, including ubiquitin-dependent protein degradation, decreased protein aggregation, and confers protection from oxidative stress. A better understanding of the proteasome
gating functions may lead to the development of novel proteasome gate-activating molecules.
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Abstract
The Ubiquitin Proteasome System (UPS) degrades individual proteins in a highly regulated
fashion and is responsible for the degradation of misfolded, damaged, or unneeded cellular
proteins. During the past 20 years, investigators have established a critical role for the UPS in
essentially every cellular process including: cell cycle progression, transcriptional regulation,
genome integrity, apoptosis, immune responses, and neuronal plasticity. At the center of the UPS
is the proteasome, a large and complex molecular machine containing a multicatalytic protease
complex. When the efficiency of this proteostasis system is perturbed, misfolded and damaged
protein aggregates can accumulate to toxic levels and cause neuronal dysfunction, which may
underlie many neurodegenerative diseases. In addition, many cancers rely on robust proteasome
activity for degrading tumor suppressors and cell cycle checkpoint inhibitors necessary for rapid
cell division. Thus clinically, proteasome inhibitors have proven useful to treat some types of
cancer, especially Multiple Myeloma. Numerous cellular processes rely on finely tuned
proteasome function, making it a crucial target for future therapeutic intervention in many diseases
including neurodegenerative diseases, cystic fibrosis, atherosclerosis, autoimmune diseases,
diabetes, and cancer. In our review, we discuss the structure and function of the proteasome, the
mechanisms of action of different proteasome inhibitors, various techniques to evaluate
proteasome function in vitro and in vivo, proteasome inhibitors in preclinical and clinical
development, and the feasibility for pharmacological activation of the proteasome to potentially
treat neurodegenerative disease.
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Prologue
Early biologists viewed cellular proteins as essentially stable constituents subjected to only minor
'wear and tear'. The widely accepted theory was that dietary proteins functioned primarily as
energy, providing fuel for the body. Rudolf Schoenheimer and colleagues challenged that notion
in the late 1930s using stable isotopes to show that trace dietary amino acids rapidly incorporated
into tissue proteins 1 and that these proteins are in a dynamic state of synthesis and degradation
2.

Today we understand that all intracellular proteins are continually “turning over;” i.e., they are

being hydrolyzed into their constituent amino acids and replaced via de novo synthesis. Individual
proteins are degraded at different rates; varying from minutes for certain regulatory enzymes, to
days for myosin heavy chain in cardiac muscle, to months for hemoglobin in erythrocytes 3. While
cytosolic proteins can be degraded in lysosomes (via chaperone-mediated autophagy and
macroautophagy), the majority are degraded by the proteasome 4.
The discovery of a special class of cytoplasmic granules containing acid hydrolases in the 50’s
5,6,

called lysosomes 7, was an important step forward in understanding intracellular protein

breakdown. Breakdown of endogenous (autophagy) and exogenous (heterophagy) material was
believed to occur in lysosomes, the 'intracellular digestive system' 8. Because, peptide hydrolysis
is an exergonic (i.e. downhill) reaction, the discovery of ATP-dependent protein breakdown in
mammalian

9

and bacterial cells

10

was unexpected. Simpson et al. suggested "the possible

existence of two (or more) mechanisms of protein breakdown, one hydrolytic, the other energyrequiring" 9. Subsequent work over the next two decades firmly established that both rates of
protein synthesis and degradation determine the cellular protein concentration as well as the wide
variability of protein half-lives 11–13.
Studies in the 1970’s supported the prediction of a new selective degradation pathway that
accounted for the wide distribution of protein half-lives

14–17.

Interestingly, cytosolic proteins
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synthesized with structural analogues of a normal amino acids are rapidly degraded within the
cell

14,18,19.

These seminal observations added another layer of selectivity in which the inherent

stability of each protein also determines the degradation rate, presumably to prevent the
accumulation of abnormal proteins 19. However, the mechanism of selectivity remained a mystery.
ATP was found to be essential for protein catabolism but it was unknown whether a proteolytic
step was directly dependent on ATP or whether it required some additional reactions 20. Selective
and ATP-dependent protein degradation was not congruent with the notion of the lysosome as
the key player in protein breakdown. What could be responsible for this exquisitely controlled
protein degradation? In 1977 Etlinger and Goldberg identified a novel, soluble, ATP-dependent
proteolytic system that was independent from the lysosome

21.

The importance of the soluble

degradation system was emphasized when Rechsteiner and colleagues showed that most
intracellular proteins are degraded in the cytosol, not the lysosome 22.
Wilk and Orlowski (1980) purified a 700 kilodalton (kDa) 'multicatalytic proteinase complex' (later
shown to be the 20S proteasome) 23. Unlike all other known proteases, this new protease complex
could cleave peptides after basic, acidic, or hydrophobic residues, suggesting that it contained
multiple distinct active sites

23,24.

Electron micrographs revealed the complex to be a 700 kDa

stacked ‘donut’ ring structure 25. Due to their critical roles in intracellular protein breakdown, these
protease complexes were collectively renamed 'proteasomes' 26. Analogous protease complexes
of equivalent size, shape, polypeptide composition, and proteolytic activities have since been
identified across all three domains of life 25,27.
The next major advancement in the field came with the discovery of ubiquitin (Ub), a small ~8
kDa protein with a big role in protein degradation. Aaron Ciechanover and colleagues identified a
small heat-stable protein, ubiquitin, covalently conjugated to target substrates
dependent manner

29,30.

28,

in an ATP-

This led to the proposed model in which protein-substrate modification

by several ubiquitin moieties targets it for degradation by a downstream, as-yet unidentified
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protease that cannot recognize the unmodified substrate

31.

It was later shown that some non-

ubiquitin proteins are also degraded in an ATP-dependent manner

32.

Rechsteiner's group later

went on to purify the ATP-dependent 26S proteasome responsible for ubiquitin conjugate
degradation 33,34.
Avram Hershko, Aaron Ciechanover, and Irwin Rose characterized the system of Ub conjugation
and its role in marking proteins for degradation
Prize in Chemistry (2004)

36.

35

– an achievement that earned them the Nobel

Attachment of poly-Ub chains to specific proteins selects them for

proteasome-mediated degradation (Figure 1A). Targeting proteins for degradation requires three
enzymatic components to link chains of Ub onto selected protein substrates. E1 (Ub-activating
enzyme) and E2s (Ub-carrier or conjugating proteins) prepare Ub for conjugation. The E3 (Ubprotein ligase) enzymes control substrate specificity, recognizing substrate degradation signals
and catalyzing the transfer of activated Ub to the substrate 35,37. Eukaryotic cells contain hundreds
of E3 ligases allowing the cell to precisely control ubiquitination and degradation of individual
proteins

38.

Ubiquitin conjugation is necessary for cell viability

39,40

and activity of the ubiquitin

pathway is greatly increased in cells making abnormal proteins 41.
During the past 20 years, investigators have established the critical role of the UPS in cell cycle
progression

42–44,

transcriptional regulation, genome integrity, apoptosis, immune responses

and the pathogenesis of many human diseases

4,46.

45,

With respect to disease, the proteasome is

particularly important for maintaining cellular protein homeostasis (i.e. proteostasis). When the
efficiency of proteostasis systems decline, misfolded and damaged proteins aggregate to toxic
levels within the cell, potentially giving rise to many neurodegenerative diseases

47,48.

Too much

of a good thing can be just as detrimental. Cancer cells rely on robust proteasome activity for
degrading tumor suppressors and cell cycle checkpoint inhibitors necessary for rapid cell division
49.

Numerous processes rely on finely tuned proteasome function, making it a crucial target for

therapeutic intervention in many diseases including neurodegenerative diseases, cystic fibrosis,
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atherosclerosis, autoimmune diseases, diabetes, and cancer

50.

In 2003 bortezomib (Velcade®)

became the first US Food and Drug Administration (FDA) approved proteasome inhibitor as a
third line treatment for multiple myeloma (MM).
In this review, we first discuss the structure, function, and regulation of the proteasome. Then we
discuss the classes and mechanisms of action of Proteasome Inhibitors (PIs). Next, we
summarize commonly used in vitro and in vivo techniques for studying proteasome activity and
inhibition followed by a review of currently FDA approved proteasome inhibitors (PIs) as well as
novel inhibitors undergoing clinical and preclinical trials. Lastly, we discuss how pharmacological
activation of the proteasome- could produce novel therapeutics to treat neurodegenerative
disease.
I. Proteasome structure and function. Overview of the current understanding of 20S/26S
proteasome structure, mechanism of protein degradation, and the cellular processes associated
with proteasome impairment or hyperactivation in human diseases.
II. Development of proteasome inhibitors. Proteasome inhibitor classes and mechanisms of
action, mechanisms of proteasome inhibitor resistance, and considerations for proteasome
inhibitor design.
III. Methods for pharmacological proteasome research. Overview of in vitro and in vivo
methods for investigating proteasome activity
IV.

Proteasome inhibitors to treat human disease. Review FDA approved proteasome

inhibitors, clinical trials, and pre-clinical research to treat cancer and inflammatory disease,
including strategies aimed at overcoming proteasome inhibitor resistance.
V. Novel proteasome pharmacological targets. Novel proteasome targets for modulating
proteasome activity.
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I. Proteasome Structure and Function
I.A. Proteasome structure and activity
The 26S proteasome is a 2.4 megadalton (MDa) molecular machine that makes up nearly 2% of
total cellular protein

51.

It is composed of a 20S proteasome core particle capped on one or both

ends by the 19S regulatory particle (Figure 1B). It degrades proteins by a multistep process; the
19S regulatory particle binds ubiquitinated substrates, opens a substrate entry gate in the 20S
52,53,

and unfolds its substrates by linearly translocating them into the 20S catalytic chamber where

they are degraded to peptides 54,55. Numerous studies over the past two decades have developed
our present understanding of proteasome structure and function. The first 20S core particle was
crystalized in the late 90's

56.

Since then hundreds of 20S structures, complexed with regulators

or inhibitors, have been solved.
Eukaryotic proteasomes contain four stacked heteroheptameric rings arranged in an α7-β7-β7-α7
fashion

56.

The amino(N)-termini of the α subunits form a "gate,” folding over the 13 Angstrom

central pore and occluding access to the proteolytic sites located on the β subunit lumen

57.

Passage through this gate is the rate limiting step and prevents unregulated protein degradation
58.

The α N-termini tails are highly conserved, containing a tyrosine-aspartate-arginine (YDR) motif

that forms salt bridges with neighboring tails that obstruct the 13A entry pore. The α3 N-terminus
is the lynchpin, critical for stabilizing the closed gate confirmation

58.

Note that the purified latent

20S proteasome still exhibits a degree of peptidase activity due to stochastic conformational
fluctuations within the N-termini

59,60.

Interestingly, deletion of the first eight α3 residues (α3∆N-

20S) sufficiently destabilizes the closed-gate conformation and accelerates the entry and
degradation of peptides

58.

α3∆N-20S crystallographic structures show that the remaining N-

termini are disordered resulting in a constitutively open gate 58. Wild type 20S proteasome activity
is similarly accelerated when bound to a proteasome activator (e.g. 19S/PA700, 11S/PA28,
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Blm10/PA200)

61.

Proteasome activators bind to a free end of the α subunit ring and "open" the

gate by distinct mechanisms that are discussed in detail below.
I.A.1. Active sites of the 20S. The eukaryotic 20S proteasome contains six proteolytically active
β-subunits, three on each β-ring that exhibit different substrate preferences (Figure 2A and 2B).
The various substrate binding pockets determine active site specificity like classical proteases but
with more complexities. The binding pockets themselves are formed by specific interactions
between the catalytic subunit and the neighboring β-subunit 62. As a result, the proteasome is not
simply a complex of independent proteases but is a unique multicatalytic enzyme functioning only
when wholly intact. The chymotrypsin-like site (β5) preferentially cleaves after hydrophobic
residues, the trypsin-like site (β2) preferentially cleaves after basic residues, and the caspase-like
site (β1) preferentially cleaves after acidic residues

55,63.

Despite their names, these sites do not

share the catalytic mechanisms of their namesakes and their substrate preferences are much
broader than the names imply 51. Multiple catalytic sites with varying specificities advantageously
allow for the rapid and processive degradation of cellular proteins.
All proteasome active sites utilize an N-terminal threonine nucleophile. Enzyme inhibitor and sitedirected mutagenesis studies compose much of what we know about the proteasome’s unusual
catalytic mechanism

64.

Although lacking the classical triad of cysteine and serine proteases,

proteasome sensitivity to peptide aldehyde inhibitors suggests a similar catalytic mechanism

64.

Accordingly, the crystal structure of the 20S bound to the peptide aldehyde Ac-Leu-Leu-nLeu-al
(ALLN) reveals a hemiacetyl bond between the β subunit N-terminal threonine hydroxyl groups
64.

Proteasome inhibitors (lactacystin, vinyl sulfones, and epoxyketones) are often found to

covalently modify this threonine. As expected, mutation to a serine residue retains significant
activity while mutation to an alanine residue completely abolishes activity

64.
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1.A.2. Specialized catalytic subunits. Some cell types express  subunits with modified catalytic
sites under certain conditions. Immune cells constitutively express alternative catalytic subunits
(β1i/LMP2, β2i/MECL-1, and β5i/LMP7) that are preferentially incorporated into the 20S
proteasome de novo in place of the constitutive β1 (β1c), β2 (β2c), and β5 (β5c) subunits, forming
the immunoproteasome

65

(Figure 2A). The immunoproteasome is also expressed in

nonhematopoietic cells when exposed to interferon (INF)-γ or tumor necrosis factor (TNF)-α

65.

To our best knowledge the main purpose of the immunoproteasome is to enhance ligand
generation for major histocompatibility complex class I (MHC-I) molecules
immune surveillance

67.

66

that allow for

How do these immune subunits do this? These subunits use the same

catalytic mechanism as their constitutively expressed counterparts but they have different
cleavage preferences due to changes in substrate binding pockets

64,68.

The most striking
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difference between constitutive and immunoproteasomes is the β1i subunit, which lacks caspaselike activity but instead cleaves after hydrophobic residues 64. This is a crucial difference because
only MHC-I molecules with tightly bound ligands are expressed on the cell surface. Tight class-I
binding requires ligands 8-9 amino acids in length with either a hydrophobic or basic anchor
residue at the carboxy(C)-terminus. Ligands with acidic C-termini are not accepted 69,70. Thus, the
immunoproteasome facilitates the production of peptides suitable for MHC-I presentation 66.
Human thymus cortical epithelial cells express a thymic-specific catalytic subunit β5t, which
together with β1i and β2i form the thymoproteasome

71

(Figure 1A). The thymoproteasome is

essential for T lymphocytes positive selection. Compared to β5c and β5i, the β5t has weak
chymotrypsin-like activity, thus it is speculated that thymoproteasomes facilitate the low affinity
MHC-I molecule ligand production necessary for positive selection

71.

Further details on unique

functions of tissue-specific proteasomes can be found in Kniepert & Groettrup (2014) 70.
1.A.3. Proteasome regulatory caps and their diverse biological roles. Regulation of gate
opening in the 20S proteasome is an important aspect of proteasome function, and as such the
cell has evolved many different proteasomal regulators that control 20S gate-opening 61. The most
well-known regulator is the 19S (also known as PA700), a component of the 26S proteasome.
The 26S proteasome is a structurally dynamic complex, adopting large-scale conformational
changes around the central axis during the ATP-dependent processing of substrates 72–75. These
structural changes appear to be necessary for substrate protein unfolding and injection into the
20S core particle.
Ubiquitin-dependent degradation requires several steps: (1) substrate binding and commitment,
(2) 20S gate opening, (3) substrate unfolding and translocation, and (4) deubiquitination (Figure
2B). (1) The 19S regulatory particle has three integral subunits that serve as substrate receptors:
Rpn1, Rpn10, and Rpn13. These substrate receptors reversibly associate with Ub, and have only
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low affinity for mono-Ub

76.

The multiplicity of Ub receptors coupled with a variety of shuttling

factors (e.g. proteins that have a ubiquitin-like domain (UBL) and a ubiquitin associating domain
(UBA)) allows the 26S proteasome to recognize and degrade many types of Ub conjugates

77.

Substrate binding to the Ub receptors induces a conformational change aligning the 19S ATPase

20

translocation channel directly over the 20S gate
hydrolysis

78,79.

73,

induces gate opening, and stimulates ATP

Substrate commitment requires a loosely folded region of the protein (e.g.

unstructured initiation site) to insert into the ATPase ring where tyrosine pore loops inside the
ATPase ring “grip” the substrate in an ATP-dependent manner

80.

(2) The six ATPase subunits

(Rpt1-6) form a ring at the bottom of the 19S complex with their C-termini inserting into the 20S α
subunit intersubunit pockets

82.

19S-dependent gate-opening requires ATPase C-terminal HbYX

motif binding to intersubunit pockets (between the α subunits) on top of the 20S 83. Binding of the
19S C-termini to the 20S is thought to induce a conformational change in the α subunits, opening
the gate

82.

The exact mechanisms behind the 26S HbYX-motif gate opening in human 26S

proteasomes are not clear. However, binding of a HbYX-motif peptide (the last 8 residues of Rpt5)
is sufficient to allosterically induce conformational changes in the 20S -subunit and open the
gate 84. (3) The six ATPase subunits power processive unfolding and translocation of substrates
into the 20S core coupled with ATP hydrolysis

85,86.

(4) Rpn11 is the integral proteasomes-

associated deubiquitinase (DUB) enzyme of the 19S complex. Rpn11 is positioned directly above
the translocation channel when substrate is committed for degradation and removes the entire
Ub chain as proteins are translocated

76.

Two other DUBs are transiently associated with

proteasomes (Usp14 and Uch37) and they can trim substrate Ub chains prior to the committed
step, rescuing the substrate from degradation 76. Proteasome associated DUBs are discussed in
Part V.
In addition to the 19S, there are two other proteasome gate activator families, the 11S and
PA200/Blm10, neither of which contain unfoldase activity or require ATP (Figure 2C). Higher
eukaryotes express three 11S regulatory subunits, PA28α,β,γ (aka REGα,β,γ)

87,88.

PA28αβ

forms inducible heteroheptamer that is primarily located in the cytoplasm. In contrast, PA28γ
forms a homoheptamer that is constitutively expressed in the nucleus 61,89. The biological roles of
these regulators remain relatively mysterious. However, both forms of PA28 regulators show
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increased expression following acute oxidative stress in cells, suggesting both play a significant
role in oxidized protein degradation 90. Additionally, IFN-γ increases PA28αβ expression, oxidized
protein degradation capacity 90, and MHC-I ligand generation.
PA200 (Blm10 in yeast) plays a role in spermatogenesis 91, response to DNA repair 92, glutamine
homeostasis 93, and mitochondrial inheritance 94, although molecular details behind many of these
functions are not clear. The crystal structure of yeast Blm10-20S shows that Blm10 forms a large
HEAT repeat-like solenoid in a 1.5 super helical turn, forming a dome that caps the ends of the
20S proteasome 94. One C-terminal HbYX motif binds between the α5 and α6 intersubunit pocket
and facilitates gate opening

95,96.

As with the 19S Rpt5 subunit, an eight-amino acid Blm10 C-

terminal fragment (Blm-pep) induces gate opening in purified 20S proteasomes

97.

The Blm-pep

bound 20S crystal structure closely resembles the bound HbYX in the full-length Blm10 structure.
PA200/Blm10 containing proteasomes specifically catalyze the acetylation-dependent, but not
polyubiquitination-dependent, core histone degradation during somatic DNA damage response
and spermatogenesis

98.

During spermatogenesis, the spermatoproteasome (formed by PA200,

20S, β1i, β2i, β5i and the human testis specific α4s) degrades core histones and is required for
proper sperm maturation and viability

98.

The existence of such proteasomes highlights the

seemingly infinite complexities of the cell’s repertoire of proteasome complexes for specific
cellular roles.
I.B. Proteasome dependent cellular processes
Proteasome function is essential to cellular homeostasis. In addition to maintaining proteostasis,
the proteasome plays a key role in the regulating many physiological processes. Four major areas
not previously discussed include cell cycle regulation, NF-κB activation, neuronal function, and
ER-associated protein degradation (Figure 3).
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I.B.1. Cell Cycle. The proteasome degrades many cell cycle regulatory proteins that typically
have short half-lives (e.g. cyclin B1, p21, p27) and tumor suppressors (e.g. p53) promoting cycle
progression 99–103. Not surprisingly, most cancers heavily rely on proteasome activity and are more
susceptible to proteasome inhibition than normal cells

104–106.

Proteasome inhibition in cancer is

discussed in Part III.
I.B.2. NF-κB Activation. The NF-κB transcription factors (NF-κB and Rel proteins) regulate
expression of genes involved in innate and adaptive immunity, inflammation, stress responses, B
cell development, and lymphoid organogenesis. In cancer cells, NF-κB is critically involved in the
expression of the antiapoptotic IAP family of genes as well as BCL-2 pro-survival genes 107–109.
23

Canonical and a non-canonical NF-κB activation requires proteasome-mediated degradation of
regulatory elements for transcriptional activation. In the unstimulated state, the inhibitory IκB
subunits bind and sequester NF-κB/Rel complexes in the cytoplasm

110.

In canonical pathway

activation, proinflammmatory cytokines activate the IKK complex (IKKβ, IKKα, and NEMO) which
phosphorylates IκB, leading to IκB ubiquitination and proteasomal degradation 111–114, freeing NFκB/RelA complexes. Freed NF-κB/RelA complexes translocate to the nucleus where they (either
alone in or combination with other transcription factors) induce target gene expression. In the
noncanonical pathway, NF-κB-p100/RelB complexes are inactive in the cytoplasm. Signaling
activates the kinase NIK, which activates IKKα complexes that phosphorylate NF-κB2-p100 Cterminal residues. Phosphorylated NFκB is ubiquitinated and processed by the proteasome into
NF-κB2-p52, which is transcriptionally competent. Such processing by the proteasome is
remarkable since it requires the initiation of protein degradation, followed by termination of
degradation at a specific domain, demonstrating exquisite control over degradation. After
processing, NF-κB2-p52 translocates to the nucleus and induces target gene expression. NF-κB
is a pro-survival pathway and is upregulated in many cancers and inflammatory diseases

115.

Given the indispensable role of proteasome function in activating this pathway, proteasome
inhibition is a valid therapeutic target. The role of NF-κB in cancer pathology is discussed further
in Part IV.
I.B.3. Neuronal function. Maintaining proteostasis in neurons is especially important due to their
complex architecture, long lifespan, and inability to dilute aggregate load through cell division

116.

Importantly, the UPS is critical for normal functioning of neuronal synapses, including synaptic
protein turnover, plasticity, and long-term memory formation, which rely on tightly controlled
changes in the proteome 116–119. In addition to the intracellular proteasomes, Ramachandran and
Margolis (2017) identified a mammalian nervous-system-specific membrane-associated
proteasome complex that rapidly modulates neuronal function

120.

This proteasome complex
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degrades intracellular proteins and releases the products into the synaptic cleft where they
stimulate postsynaptic N-methyl-D-aspartate receptor-dependent neuronal signaling, a process
important for regulating synaptic function.
The accumulation of aggregation-prone proteins is a hallmark of neurodegenerative disease
commonly accompanied by loss of proteostasis and progressive death of neurons

121–123.

It is

established that proteasome function is decreased in neurodegenerative diseases, and its
impairment is implicated in the development of many neurodegenerative diseases including
Alzheimer’s, Parkinson’s, and Huntington’s diseases

122,124–127.

To highlight this point, brain

region-specific proteasome inhibition closely mirrors the neuropathology and clinical hallmarks of
neurodegenerative diseases

128–131.

The importance of targeting the proteasome for potential

neurodegenerative disease therapy is discussed in Part V.
I.B.4. Endoplasmic reticulum-associated protein degradation and the unfolded protein
response. Secretory proteins and most integral membrane proteins are synthesized and enter
the endoplasmic reticulum (ER) lumen for proper folding and covalent modifications. The ERassociated protein degradation (ERAD) pathway is an evolutionarily conserved process that
discards misfolded ER proteins

132.

Three different ERAD pathways (ERAD-L, -M, and -C) are

utilized for degrading misfolded ER proteins, depending on whether their misfolded domain is
localized in the ER lumen, within the membrane, or on the cytosolic side of the ER membrane,
respectively

133–135.

A fourth pathway is responsible for misfolded protein removal from the inner

nuclear membrane 136,137. Each pathway involves distinct Ub ligases and co-factors, although it is
unclear how proteins are targets to each pathway. ERAD substrates from all pathways are
retrotranslocated to the cytosolic side of the membrane

132.

With the help of ubiquitination

machinery and the Cdc48/p97 ATPase complex, the substrates are extracted from the membrane
and delivered to the 26S proteasome for degradation

138–141.

Proteasome inhibition stalls ERAD

and causes misfolded proteins to accumulate within the ER. In response, the cell activates a
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highly conserved signaling pathway called the unfolded protein response (UPR)

142.

Multiple

physiological conditions also lead to accumulation of misfolded proteins in the ER and subsequent
UPR activation, including hypoxia, glucose deprivation, oxidative stress, and mutations in certain
secretory proteins

142.

UPR activation regulates the gene expression involved in protein folding

(e.g. chaperones) and ERAD, and decreases protein translation into the ER in an attempt to
restore ER homeostasis

143.

The UPR initially performs a protective role in the cell. However,

prolonged ER stress and UPR activation eventually leads to cell death

143.

Wu and Rapoport

(2018) recently published an extensive review discussing the molecular mechanisms of ERAD
and associated protein degradation 132.
II. Development of Proteasome Inhibitors (PIs)
II.A. The Rise of Proteasome Inhibitors
Our understanding of the importance of the UPS for biological functions and processes rapidly
advanced with the introduction of the first proteasome inhibitors 144. These valuable tools allowed
researchers to interrogate proteasome function in complex cellular systems and tissues, and
greatly advanced our understanding of many aspects of cell regulation, disease mechanisms, and
immune surveillance

66.

Perhaps the most clinically important developments to come from the

early proteasome inhibitor studies were advancements in understanding the regulation of NF-κB
and its key role in the pathogenesis of many inflammatory and neoplastic diseases 27,145. The first
proteasome inhibitors were simple hydrophobic peptide aldehydes (analogues of serine protease
inhibitors) designed to mimic the preferred substrates of the proteasome's chymotrypsin-like site
(β5) and inhibit it

27.

The tri-peptide aldehyde, MG132 (carbobenzyl-Leu-Leu-Leu-aldehyde), is

still the most widely used proteasome inhibitor in scientific research because it is potent,
inexpensive, and quickly reversible

27.

Given the indispensable role of the proteasome in this

pathway, proteasome inhibitors showed therapeutic potential for the treatment of some human
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diseases, yet it was also appreciated that complete proteasome inhibition would lead to cell death
27.

Researchers hypothesized that partial and reversible inhibition of the proteasome might be
beneficial in killing neoplastic cells because they lack many of the checkpoint mechanisms that
protect normal cells from apoptosis

27,146.

Accordingly, proteasome inhibitors were preferentially

toxic to transformed and patient derived malignant cell cultures rather than their non-transformed
and healthy counterparts

146,147.

Aldehyde proteasome inhibitors (e.g. MG-132) had limited

therapeutic potential in humans due to off-target effects (e.g. inhibition of cathepsin B and
calpains) and poor metabolic stability 148. With MG-132 as a lead compound, a team of medicinal
chemists led by Julian Adams synthesized PS-341 (a dipeptide boronic acid), a slowly reversible
inhibitor of the β5 active site (with some activity toward the β2 active site). PS-341 proved to be
a potent and selective proteasome inhibitor demonstrating therapeutic activity in preclinical
models of inflammatory diseases and human cancers

146,147,149.

PS-341 entered phase I clinical

trials where remarkably one patient with multiple myeloma (MM) showed a complete response to
PS-341 treatment 146. MM is an incurable plasma cell malignancy and at that time patients had a
poor prognosis due to lack of effective treatment options, making the complete response to PS341 a dramatic clinical breakthrough

27.

PS-341 progressed to phase II trials for MM and chronic

lymphoid leukemia. Due to the remarkable success of PS-341 in phase II trials, the FDA approved
PS-341 (later renamed bortezomib and marketed it as Velcade®) (Figure 4A) as a third-line
treatment for relapsed and refractory multiple myeloma (RRMM) in 2003

27.

Bortezomib

revolutionized the treatment of MM and today bortezomib is approved for use as a first line therapy
for MM and mantle cell lymphoma.
Despite the clinical success in treating hematological diseases, bortezomib therapy is associated
with a high rate of resistance (primary or secondary) and serious dose-limiting toxicity which
require reduction or discontinuation of the drug

150.

Advances in proteasome inhibitor chemistry

27

and a better understanding of the proteasomes unique catalytic mechanism have led to the
development of second generation proteasome inhibitors with improved pharmacokinetics when
compared to bortezomib

151.

The mechanisms of available PIs and their uses in research and

clinical settings are discussed in the following sections.
II.B. Chemical Classes of Proteasome Inhibitors
There are several classes of proteasome inhibitors. Like the majority of protease inhibitors, most
proteasome inhibitors are short peptides designed to fit into the substrate binding site on the
catalytic subunit. The activity of proteasome inhibitors depends on the pharmacophore warhead
at the C-terminus, which reacts with the active site threonine nucleophile to form a reversible or
irreversible covalent adducts

51.

Although the proteasome has three types of catalytic sites,

inhibition of all three is not required to significantly affect protein degradation

152.

Specific β1 or

β2 inhibition does not have a significant effect on overall protein breakdown, however, β5
inhibition results in significantly reduced protein breakdown

152.

Consequently, most proteasome

inhibitors target the β5 site, although they often have some lesser activity against β1 and/or β2
152.

II.B.1. Peptide Aldehydes. Based on the well-characterized serine and cysteine protease
inhibitors, peptide aldehydes (e.g. MG132) were the first synthesized proteasome inhibitors.
MG132 is cell-permeable and a reversible proteasome inhibitor, which makes it a valuable
research tool. Because MG132 has slow binding and fast dissociation kinetics (Kisselev and
Goldberg, 2001), the effects of MG132 proteasome inhibition on cultured cells is quickly reversed
by switching to inhibitor-free media. The low cost and rapid reversibility make MG-132 the most
used proteasome inhibitor for research 27. However, there are several limitations to MG-132. First,
MG-132 in cell culture media is rapidly oxidized into an inactive acid

51.

For long cell culture

experiments, MG-132 containing media should be replaced daily. Second, as other peptide
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aldehydes, MG-132 also inhibits (albeit with much lower affinity) calpains and cathepsins

51,

therefore it is necessary to perform control experiments to confirm that the observed effects are
due to proteasome inhibition. Proteasome involvement can be verified using a more selective
proteasome inhibitor (e.g. epoxomicin, boronates, and lactacystin), although these compounds
may be cost prohibitive for routine studies/screens. Additionally, inhibitors that specifically block
other proteases (e.g. E-64 for calpains), but not the proteasome, can be used to confirm the
observed effect is not due to off target inhibition of another protease.
II.B.2. Peptide Boronates. Peptide boronates are significantly more potent proteasome inhibitors
when compared to peptide aldehydes. Like peptide aldehydes, peptide boronates form a
tetrahedral adduct with the active site threonine, but their dissociation rate is much slower making
boronates practically irreversible over hour scale time courses

51.

MG-232, the boronate version

of MG-132, is 100-fold more potent than its aldehyde counterpart

51.

Additionally, peptide

boronates are not oxidized into inactive forms like MG-132, making them more stable in vivo

51.

The boronate pharmacophore cannot react with active site cysteines, so they have fewer nonproteasome targets 51.
II.B.3. Epoxomicin & Epoxyketones. Another naturally derived proteasome inhibitor is
epoxomicin, an actinomycete fermentation metabolite. It is a modified peptide that contains a C
terminal ',' -epoxyketone group attached to an aliphatic P1 amino acid

51.

Epoxomicin is

extremely specific for the proteasome. The crystal structure of yeast 20S proteasome in complex
with epoxomicin revealed its unusual mechanism of action and explained the basis for
proteasome specificity

57.

Epoxomicin reacts covalently with both the catalytically active N-

terminal threonine hydroxyl and the free amino group, producing a highly stable and irreversible
morpholino ring 57. Unlike other PIs that only form a bond with the threonine hydroxyl, the double
covalent bond formation of the epoxyketone group limits its reactivity to the N-terminal nucleophile
threonine proteases without inhibiting any other cellular protease

64.

Since the discovery of

29

epoxomicin as a proteasome inhibitor many ',' epoxyketone electrophiles have been
incorporated into peptides sequences and optimized for binding to the proteasome  subunits .
The most well-characterized epoxyketone inhibitor is carfilzomib (Kryopolis®, Onxy Pharm /
Takeda) (Figure 4A), a second-generation FDA approved proteasome inhibitor for treatment of
RRMM and is discussed further in Part IV.
II.B.4. Lactacystin and beta-lactone. Lactacystin, a Streptomyces metabolite, is a non-peptide
proteasome inhibitor. Lactacystin itself does not inhibit the proteasome, but at neutral pH
lactacystin spontaneously converts to clasto-lactacystin-β-lactone which is reactive with the
proteasome. The β-lactone reacts with the proteasome active site threonine resulting in opening
of the β-lactone ring and acylation of the proteasome catalytic threonine hydroxyl

64.

The yeast

20S proteasome in complex with lactacystin crystal structure confirmed this mechanism providing
strong evidence that an acyl enzyme conjugate is an intermediate in proteasome catalysis

64.

Lactacystin is more proteasome-specific than MG132, with a single off target substrate, cathepsin
A. Although lactacystin is considered an irreversible proteasome inhibitor, its adduct is slowly
water hydrolyzed (t1/2 ~20hr). Lactacystin is the least stable of the proteasome inhibitors and exists
in vivo in equilibrium with lactathione, its glutathione reaction product

51.

Despite this drawback,

the high proteasome selectivity makes lactacystin a viable proteasome inhibitor for investigating
the role of the proteasome in cellular processes.
II.B.5. Vinyl sulfones. Peptide vinyl sulfones are a class of irreversible proteasome inhibitors.
Peptide vinyl sulfones also inhibit cysteine proteases (e.g. cathepsins), but changing the
functional groups in the inhibitor’s peptide portion can modulate their specificity 153. For example,
replacing the benzyloxycarbonyl (Z) group with the 3-nitro-4-hydroxy-5-iodophenylacetate (NIP)
group in ZLVS (Z-Leu3-VS) generates NLVS significantly reducing inhibition of cathepsins B and
S 51. Peptide vinyl sulfones are easy and inexpensive to synthesize, and their irreversible binding
makes them attractive as protease activity probes. Peptide vinyl sulfones are commonly labeled
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with fluorophores, biotin, or a radioactive moiety, and specific uses as proteasome activity probes
are discussed in Part III. Interestingly, vinyl sulfones are more potent and more trypsin-like siteselective inhibitors than epoxyketones with an identical peptide sequence 154, a feature exploited
in the development of β2 specific proteasome inhibitors, as discussed in Part IV.
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II.C. Considerations for proteasome inhibitor design
In this section we review the structural features that have been exploited to design specific
inhibitors of the 20S catalytic sites.
II.C.1. Substrate binding pockets. All six proteasome catalytic subunits (constitutive and
immune) have a similar substrate binding site topology, in which the S1 position is buried in the
subunit next to the threonine, the S2 is solvent exposed, and both the catalytic subunit and its
neighbor contribute to the S3 binding position

155

(Figure 4B). However, residues that make up

the S1 and S3 sites have very different catalytic subunit properties. Modification of the P1 and P3
sites on a proteasome inhibitor can significantly alter their subunit specificity and affinity. The β5c
prefers a small hydrophobic group in P1 and a large hydrophobic group in P3, whereas β5i favors
the inverse arrangement

64.

Therefore, altering the hydrophobic group size in P1 and P3 confers

selectivity for β5c or β5i. Due to solvent exposure in the P2 position, it can accommodate a range
of moieties without affecting proteasome binding and is often the site for modifications aimed at
improving inhibitor solubility and stability. P2 is also a useful attachment site for fluorescent
probes, biotin tags, or azide handles (discussed further below).
II.C.2. Structural analysis of bound inhibitors. Knowledge of protein structure and its
interaction with ligands, guides drug discovery and design. X-ray crystallography is an excellent
method for obtaining high resolution proteasome structures in complex with inhibitors and has
been instrumental in understanding proteasome function and advancing proteasome inhibitor
development 62. The early structures of ALLN and lactacystin bound proteasomes provided clues
as to the threonine catalytic mechanism and intermediate states

62.

The structures of a substrate

analog bound proteasome showed long range allosteric changes that occur upon substrate
binding in the active site. The inhibitor-bound structure can be used together with biochemical
data for structure-activity relationship (SAR) studies and subsequent lead compound optimization.
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There are drawbacks to using crystallography to study proteasome inhibitor - proteasome
interactions. First, solvent conditions and inhibitor concentrations used in co-crystallization are
not physiological and should be considered when interpreting the resultant structure. 20S
proteasome crystals are usually soaked in solutions with high inhibitor concentrations under
conditions that preserve crystal integrity, whereas enzymatic assays are carried out at 37 oC with
low inhibitor concentrations and proteasomes under conditions optimized for substrate
degradation. Discordant data in the yeast 20S proteasome structure in complex with Ac-LLN-al
showed the inhibitor bound to all six proteasome active sites, but the biochemical data indicated
that Ac-LLN-al proteasome inhibitor preferentially inhibits the β5 site (with very low activity against
the β1 and β2) unless used at extremely high concentrations

64.

If one considers that most

proteasome inhibitors affects multiple active sites at high concentrations and that proteasome
inhibitor concentration in the crystallization condition was in the millimolar range, it is unsurprising
that the inhibitor bound all sites. This example illustrates the necessity to carefully consider
existing biochemical data when interpreting new structures.
Additionally, obtaining good diffraction data relies on homogenous crystal packing. Under these
conditions, one may miss larger scale conformational changes that take place upon 20S
proteasome ligand binding. The inherent drawbacks in crystallography methodology highlight the
need to incorporate other structural methods into understanding the proteasome. Recent
advances in cryo-electron microscopy (EM) and single particle analysis make it possible to obtain
near atomic level resolution protein structures in more physiological conditions

156.

Proof of

principle for the cryo-EM utility in structure-based drug discovery and development is found in 157.
Recently, the noncovalent reversible asparagine-ethylenediamine (AsnEDA)-based inhibitor
bound human immuno-proteasome cryo-EM structure was used in SAR studies

157.

Exploiting

β5c/β5i residue differences near the S1 pocket improved PKS21187 affinity for β5i down to 15
nM (from 58 nM) and successfully improved selectivity (20 fold) over β5c

156.

Although cryo-EM
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typically cannot provide quite the same resolution as crystallography, the 20S core particle
characteristically has high local resolution (~3Å, in both above studies) at the interior of the β
subunits, making this a valuable method for investigating proteasome ligand binding under
relatively physiological conditions.
It is important to keep in mind that cryo-EM structures are derived from averaging classes of
particles, meaning that protein sub-conformations may be overlooked. This is important in
interpreting 26S proteasome structures because the complex undergoes large-scale
conformational changes during cycles of substrate binding and ATP hydrolysis, resulting in many
conformational states coexisting simultaneously. Despite physiologically relevant conditions,
conformer subpopulations may not be apparent. For example, Baumeister and colleagues
published 26S proteasome in the ATP-hydrolyzing state
structures

72.

74

and the ATP-γS bound cryo-EM

However, when they performed a deep classification of more than 3 million 26S

proteasome particles in the presence of both ATP and ATP-γS they identified a third state of the
26S proteasome that was believed to be an intermediate conformation during the ATP hydrolysis
cycle

158.

Additional intermediate 26S conformations states have been identified in humans and

yeast using cryo-EM 159–161.
II.C.3.

Proteasome

inhibitor

pharmacophore

properties.

As

previously

discussed,

pharmacophores confer specific proteasome inhibitor properties including compound stability, off
target protease inhibition, and inhibition kinetics. Interestingly, the pharmacophore nature is
suggested to influence proteasome inhibitor active site specificity.

Epoxyketone warhead

replacement with vinyl sulfone moieties in β5 inhibitors further improves β5 site (but not β5i site)
selectivity 153. Therefore, each warhead confers unique properties to the proteasome inhibitor and
thus careful considerations needs to be made when selecting a pharmacophore along with
appropriate controls.
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III. Methods for pharmacological proteasome research
Extensive methodology exists for investigating proteasome function in vitro and in vivo. Here, we
describe some commonly used methods for proteasome purification, peptidase activity assays,
and protein degradation assays in vitro and in cell culture, and discuss their advantages and
limitations.
III.A. Proteasome purifications
Rigorous and reproducible studies of proteasome pharmacology require a source of pure and
active proteasomes. The following is a summary of methods for endogenous and affinity tagged
proteasome purifications.
III.A.1 Endogenous proteasome purification. Endogenous proteasomes are purified from a
variety of tissues using a series of anion exchange chromatography columns. After purification,
20S and 26S proteasomes are separated by gel filtration or glycerol gradient centrifugation.
Because 26S proteasomes require ATP hydrolysis to remain intact, omitting ATP from the
homogenization and chromatography buffers enriches for 20S proteasomes. Rabbit skeletal
muscle and bovine liver have abundant proteasomes making it possible to obtain pure
proteasomes (>95%) in milligram quantities in under a week. Most 20S proteasome preparations
still use this method today.
Another method to purify endogenous 26S proteasomes from almost any tissue or cell type takes
advantage of the 19S regulatory particle’s affinity for proteins containing ubiquitin-like (UBL)
domains

162.

Recombinant glutathione S-transferase (GST) fused to the ubiquitin-like (UBL)

domain of ubiquitin shuttling factor RAD23B is purified from E. coli and bound to glutathione
beads. 26S proteasomes in cell or tissue lysates bind the GST-UBL column while all other cellular
proteins are washed away. Bound 26S proteasomes are subsequently eluted by adding high
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concentrations of a tandem ubiquitin-interacting motif (UIM) derived from the 19S ubiquitin binding
subunit, Rpn10

162162.

Unlike anion exchange chromatography (which takes ~3 days), the UBL-

affinity method is completed in a single day without high salt buffers. Rapid and gentle 26S
purification is essential to retain loosely associated proteasome proteins which are lost during
anion exchange chromatography.
Because the GST-UBL bait occupies UBL binding sites on the 19S, endogenous UBL domain
containing proteins and Ub-conjugates may be dislodged from the proteasome upon purification
163.

Despite this limitation, the UBL-affinity method has been valuable in studies investigating 26S

proteasome composition in a variety of physiological and disease states. For example, Qiu et al.,
(2006) used the UBL-affinity method to identify Rpn13 164, a novel human 19S subunit that tethers
and activates UCHL5 (a deubiquitinase) to the 26S proteasome and functions as a ubiquitin
receptor

165.

The UBL-affinity method also co-purifies other important proteasome associated

proteins with important roles in regulating proteasome function and Ub-conjugate degradation
(e.g. the deubiquitinase USP14) 163. A significant advantage of the UBL-affinity method is that you
can purify proteasomes from diseased tissues and study the changes in proteasome activity and
composition without genetic alterations.
Most commercially available 20S and 26S proteasomes are purified from mammalian (e.g.
human, rabbit) erythrocytes. Since erythrocytes lack nuclei, these endogenous proteasomes are
"aged", perhaps with oxidative damage, and may have lower basal activity than those derived
from nucleated cells.
III.A.2 Affinity-tagged proteasomes. Several groups have created human cell lines and yeast
strains stably expressing affinity tagged proteasome subunits to rapidly isolate proteasomes for
structural and functional studies. Affinity tags are often appended to the C-termini of Rpn11 or β4
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because modifications on these subunits do not cause any discernable effect on proteasome
function in cellular or yeast cultures.
Affinity-tagged proteasome purifications are especially useful for studies of changes in 26S
proteasome composition because they typically co-purify with more Ub-conjugates and additional
proteasome-interacting proteins than UBL-affinity or ion exchange chromatography methods. For
example, Leggett et al., (2002) used a TEV-protease cleavable Protein A derived tags on Rpn11,
Rpt1, and β4 to study how proteasome interacting proteins (PIPs) regulate the stability of the
yeast 26S complex in vivo

167.

The high purity and yield of affinity-tagged proteasomes is well

suited for cryo-EM studies. For example, Matyskiela et al., (2013) used cryo-EM analysis of
Rpn11-3xFLAG yeast proteasomes to study the conformational dynamics during 26S substrate
engagement

75.

Affinity tags are also amenable to high purification efficiency of crosslinked

complexes under fully denaturing conditions. Guerrero et al., (2006) designed a tandem affinity
tag consisting of a hexahistidine sequence and an in vivo biotinylation signal (HB)

168.

Tandem

affinity purification of Rpn11-HB proteasomes after in vivo cross-linking was combined with
tandem mass spectrometry (MS) and quantitative SILAC (stable isotope labeling of amino acids
in cell culture) to globally map the 26S proteasome interaction network in yeast

168.

A TEV-

cleavable version of the HB tag (HTBH and HBTH) allows for one-step purification of human 26S
proteasomes. Wang et al., (2017) generated several stable HEK293 cell lines expressing tagged
subunits (e.g. Rpn11-HTBH, HBTH-Rpn1, HBTH-Rpt6)

170.

They used these cells lines with in

vivo and in vitro crosslinking-MS workflows and cryo-EM approaches to comprehensively
examine protein-protein interactions within the 26S proteasome

169.

Choi et al. (2016) developed

stable β4-HTBH/α3-FLAG and β4-HTBH/α3ΔN-FLAG HEK293 cell lines

171.

The α3 N-terminal

deletion (α3ΔN) results in a constitutively open gate. These cell lines are an excellent tool for
investigating the role of dynamic proteasome gating, and are discussed further in Part V. It is
worth noting that most of these cell lines stably express the tagged subunit in addition to the
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endogenous gene, thus purification does not isolate all proteasome complexes and may not
reflect all changes in proteasome composition under different physiological states or drug
treatments.
III.A.3. Immunoproteasomes. Immunoproteasome preparations are usually purified from
spleens and cell cultures treated with IFN-γ to increase immunoproteasome subunit expression.
Immunoproteasomes can be purified using the same anion exchange chromatography methods
as described above for constitutive proteasomes. However, constitutive proteasomes are
ubiquitously present in all tissue types and even low amounts can interfere with
immunoproteasome-specific research. Dechavanne et al., (2013) report that hydrophobic
interaction chromatography can successfully separate immunoproteasomes from residual
constitutive proteasome contamination after purification 172.
III.A.4. Validating and storing proteasome preparations. It is imperative to check for
contaminating proteases in all proteasome preparations. For example, the anion exchange elution
profile of tripeptidyl-proteases (TPP) overlaps with proteasomes. TPP is a serine protease and
capable of cleaving fluorogenic peptides (e.g. Suc-LLVY-amc, Ac-AFF-amc). Proteasome specific
activity can be verified with proteasome inhibitors as a negative control.
Regardless of the purification method, it is necessary to confirm the 20S/26S proteasome
assemblies in your preparation. For example, purifying affinity tagged RPN11 proteasomes will
select for single capped 20S, double capped 20S, and free 19S particles, while affinity tagged
20S subunits selects for free 20S, 26S, and 20S associated with other regulators (e.g. PA28,
PA200). 20S proteasomes and 20S bound to regulators are clearly separated by native-PAGE
(e.g. NuPAGE® 3-8% tris-acetate gel)

162.

Electrophoresis with 26S proteasomes are performed

at 4oC with adequate ATP and MgCl2 in the buffer to prevent complex dissociation (Table 1). After
electrophoresis peptidase activity of proteasome complexes is measured by an in-gel
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fluorescence activity assay

162.

The gel is incubated at 37oC in buffer containing the fluorogenic

peptide substrate Suc-LLVY-amc and the cleaved amc fluorophore is visualized with ultraviolet
light. Adding 0.02% sodium dodecyl sulfate the gel incubation buffer enhances 20S peptidase
activity and improves visualization of the 20S band. After UV imaging, the gel can be processed
with coomassie/silver stain, analyzed by 2D native-SDS-PAGE, or transferred to a membrane for
immunoblot analysis. Due to the large size of the proteasome complexes (700kDa-2.4MDa),
incubating the gel in SDS buffer prior to transfer may improve transfer efficiency and increase
epitope availability. Roelofs et al., (2018) provide methods for various downstream analyses to
investigate the activity and composition of proteasome complexes separated by native-PAGE 173.
The association between the 19S and 20S is labile and sensitive to changes in temperature and
presence of nucleotides. To support integrity of 26S proteasome complexes, purification should
be performed as rapidly as possible in the presence of adequate ATP and MgCl2 and always at
4oC. Addition of glycerol (~10%) in the proteasome purification and storage buffers stabilizes the
26S complexes and the latent 20S gate. After purification, both 20S and 26S proteasomes should
be flash frozen in liquid nitrogen, stored at -80oC, and never refrozen once thawed. It is important
to thaw frozen 26S proteasomes on ice and use them immediately after thawing. Since freezing
and storage conditions can affect the labile 26S proteasome assembly, we recommend verifying
the assembly state of your 26S preparation after thawing with native-PAGE.
III.B. Monitoring proteasome activity
There are numerous methods for monitoring proteasome activity in vitro and in vivo. In vitro
experiments are performed with either peptide-based or protein-based model substrates. The
following section covers commonly used peptide and protein-based model proteasome substrates
and methods for monitoring their degradation. Lastly, we will discuss artificial proteasome
substrates for expression in cell culture and transgenic animals.
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III.B.1. Peptide-based model substrates: In vitro proteasome activity is often measured using
a fluorescent substrate enzyme activity assay. Peptide substrates are useful for monitoring
proteasome gating and peptidase activities and are amenable to high throughput formats. Model
peptide substrates are short tri- or tetrapeptides with a C terminal fluorophore (e.g. 7‐amino‐4‐
methylcoumarin, amc). The amino acid sequences are designed to preferentially interact with and
be degraded by specific 20S subunits (Table 2, Figure 2B). Common peptide substrates are SucLLVY-amc (Succinyl-leucine-leucine-valine-tyrosine-amc), Boc-LRR-amc (Tert-butoxycarbonylleucine-arginine-arginine-amc),

and

Ac-nLPnLD-

aminoluciferin (N acetyl-norleucinal-proline-norleucinalaspartate-amc) for the β5 chymotrypsin-like, β2 trypsinlike and β1 caspase-like activities, respectively. However,
it is important to note that at high substrate concentrations
multiple active sites can participate in substrate cleavage.
The amc moiety is quenched at the excitation wavelength
(ex: 380nm) when attached to the peptide, and proteolytic
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cleavage enhances fluorescence (em: 460nm). Changes in fluorescence intensity are monitored
in real time using a microplate reader. The increases in fluorescence intensity is directly
proportional to proteasome proteolytic activity. This assay is rapid and suitable for high-throughput
studies. Cell-based reagent kits use similar aminoluciferin-fused peptide substrates which allows
measurement of proteasome peptidase activity in intact cells.
Although fluorescent substrate peptides are an excellent tool for preliminary studies measuring
proteasome activity (e.g. screening compound libraries), there are several pitfalls. Foremost,
small peptides bypass the need for 19S recognition and unfolding and thus report on only 20S
peptidase activities. Furthermore, changes in peptide hydrolysis does not necessarily correlate
with changes in protein degradation, and it is important to note that at high peptide substrate
concentrations multiple active site types can participate in peptide cleavage. As such,
chymotrypsin-like (β5) activity (Suc-LLVY-amc) assays evaluating response to a proteasome
inhibitor may overestimate the reduction in protein degradation in vivo. Therefore, it is imperative
to evaluate the experimental effects with full length protein degradation and not rely solely on
peptide hydrolysis data.
III.B.2. Protein based model substrates. Many protein substrates are available for monitoring
20S and 26S proteasome degradation in vitro (e.g. using purified proteasomes or cellular lysates).
Here we describe methods for quantitating protein degradation and give examples of model
substrates for 20S and 26S proteasome activity.
Methods to quantitate protein degradation. The extent of in vitro protein degradation can be
measured in several ways. The fluorescamine assay is a quantitative method for measuring
protein cleavage products generated by the proteasome. The proteasome processively degrades
proteins and the products generated equals the number of substrate molecules degraded
multiplied by the mean number of cuts made in a single polypeptide

152.

Fluorescamine addition
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to an amine free assay buffer quickly labels new N-termini amines on short peptides generated
by proteolytic cleavage.
Alternatively, the proteins can be separated by SDS-PAGE and monitored for substrate band
disappearance via coomassie staining, silver staining, or immunoblot. Care must be taken when
monitoring degradation via western blot, as degradation of the epitope results in complete loss of
signal, which may not corollate with complete protein degradation. Since most gel-based protein
degradation assays are performed with small reaction volumes (<20 µL) incubated in centrifuge
tubes, the amount of substrate remaining should be normalized to a loading control (e.g. a 20S
proteasome subunit) to control for loss of substrate protein during pipetting or incubation steps.
Fluorescence anisotropy is useful to follow the degradation of fluorescent dye labeled protein
substrates of 20S and 26S proteasomes in real time

174,175.

Bhattacharyya et al. (2018) describe

methods for high throughput measurement of 26S ubiquitin-dependent degradation using dye
labeled substrates 174.
20S substrates (19S independent). For example, β-casein is a good substrate for monitoring 20S
protein degradation since it is unstructured, thus abrogating the requirement for the unfoldase
activity associated with the 19S regulatory particle and is commercially available.
26S (ubiquitin independent) substrates. Folded substrates are required to determine the
contribution of 19S activities toward 26S proteasome degradation. Ornithine decarboxylase
(ODC) is a stably folded protein containing a C-terminus degradation tag
Ub-independent degradation by 26S proteasomes

177.

176

that promotes rapid

Fusing the ODC degradation tag (cODC)

to other proteins promotes their proteasomal degradation

178.

For example, cODC fusion to the

titin I27 domain allows for testing of the ubiquitin-independent degradation of a folded protein,
though the kinetics may be slow

179.

Destabilizing mutations can be introduced to I27 and

accelerate substrate degradation 179.
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26S (ubiquitin dependent) substrates. The 26S ubiquitin-dependent degradation of folded
proteins can be monitored with a tetra-ubiquitin fused green fluorescent protein (GFP)

180

with a

c-terminal unstructured region 181 or a tetra-ubiquitinated dihydrofolate reductase (DHFR) 182. It is
also possible to express some cODC fusion proteins in vivo to monitor proteasome activity.
III.B.3. Proteasome activity in cell culture. The 26S proteasome degrades ubiquitinated
proteins and proteasome impairment leads to poly-ubiquitinated protein accumulation. Measuring
changes in high molecular weight poly-ubiquitin protein conjugates via immunodetection is a
method to monitor changes in proteasome activity. This is a general, non-specific method to
measure changes in proteasome degradation and should not be used alone to assess
proteasome activity.
Stable expression of GFP-fusion reporters is commonly used in cell culture to monitor proteasome
activity. Measuring fluorescent reporters is a well-established technique for monitoring
proteasome activity. Changes in reporter protein levels (in the absence of translation changes)
inversely reflects degradative capacity of the UPS. Wild type GFP has a long half-life in
mammalian cells and therefore is not a suitable proteasome degradation substrate for most
experiments. Several GFP-fusion proteins have been engineered as specific proteasome
substrates (Table 3). Bence et al. (2005) designed a synthetic reporter consisting of the short
degron, CL1
184,

183,

a consensus sequence for ubiquitination that was first identified in fission yeast

fused to the C-terminus of GFP (GFPu), thereby targeting it for ubiquitin-dependent

proteasome degradation

183.

Addition of the CL1 degron converted the GFP half-life from ~10

hours to ~30 minutes. Cell compartment-specific proteasome function can be monitored by
localization of GFPu directed to the nucleus (NLS- GFPu), the cytoplasm (NES-GFPu) 183,185, or to
neuronal synapses (PSD95- GFPu and SNAP25- GFPu) 186 (Table 3).
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Other UPS reporters have been generated to determine targeted proteasome degradation using
different pathways. The N-end rule relates the cellular protein half-life to the identity of its Nterminal residue

187.

Fluorescent substrates of the N-end rule degradation pathway have been

created with ubiquitin-GFP fusion constructs. When these ubiquitin fusion proteins are expressed
in cells, deubiquitinases rapidly cleave the ubiquitin and expose an unmodified N terminal GFP
residue. N terminal arginine residue exposure (e.g. the substrate Ub-R-GFP) recruits UBR E3
ligases which ubiquitinate the protein, targeting it for proteasome degradation 188. Techniques for
generating ubiquitin fusion proteins with varying half-lives and conditional mutants are described
in

189,190.

Unlike Ub-R-GFP, the reporter UbG76V-GFP cannot be deubiquitinated (thereby

bypassing the N-end rule pathway) and is a model substrate for the in vivo Ub fusion degradation
(UFD) pathway

188.

The T cell receptor protein α chain is rapidly degraded in nonhematopoietic

cells, and a TCRα-GFP fusion protein can monitor ERAD specific proteasome activity 191. Protein
synthesis also influences the steady state protein levels, and synthesis rates can be affected by
cellular stress, transfection efficiency, and varies from cell to cell. Therefore, it is imperative to
utilize appropriate experimental design to take expression and translation differences into account
when monitoring protein degradation. Commonly used methods are pulse-chase experiments,
cycloheximide chase experiments, bicistronic constructs, or the parallel measurement of stable,
long lived fluorescent reporters. Lastly, each substrate only illustrates a single degradation
pathway, which may or may not accurately reflect the UPS perturbations within a cell. It is
advantageous to consider the use of multiple such proteasome substrates to confirm findings.
In addition to cellular proteasomal activity, proteasome localization and dynamics can also be
monitored with fluorescently labeled proteasome subunits. Both α and β subunits can be fused to
a fluorescent protein and have been shown to efficiently incorporate into proteasome particles.
For example, α4-YFP

192

and a CFP-tagged β1i

193

have been used to monitor localization
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dynamics of constitutive and immunoproteasomes in living cells. Detailed methods for monitoring
proteasome dynamics in living cells are described elsewhere 194.

III.B.4. In vivo proteasome activity. Transgenic animals that carry UFD proteasome substrates
have also been generated and are used to study proteasome function in live tissues

195,196.

Detailed methods for monitoring UFD protein degradation in yeast, cell lines, and transgenic mice
are described in Menendez-Benito et al. (2005)

197.

The photoactivatable UbG76V-dendra2

construct monitors proteasome activity independent of translation and has been successfully used
in transgenic C. elegans to determine tissue specific proteasome degradation rates 198.
III.C. Proteasome active site probes
Activity based probes (ABP) recognize catalytic sites on the constitutive or immuno-proteasomes
without requiring genetic techniques. Most proteasome ABP probes are modified proteasome
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inhibitors with a fluorescent molecule incorporated at or near the N-terminus. ABPs have been
developed that can distinguish specific constitutive and immunoproteasome subunits

199.

After

proteasome labeling and SDS-PAGE protein separation, the modified proteasome subunits are
immediately visualized via in-gel fluorescence or immunoblotting. Furthermore, cell permeable
ABPs are compatible with live-cell imaging to detect real-time proteasome localization or flow
cytometry-based experiments. Site selective ABPs are useful in determining novel proteasome
inhibitor subunit specificity. A recent review provides a detailed account of currently available
APBs196.
IV. Proteasome inhibitors to treat human disease
IV.A. Hematological Malignancies
IV.A.1. Bortezomib & Multiple Myeloma. At therapeutic doses, bortezomib inhibits
approximately 30% of proteasome mediated protein degradation

146,

which is sufficient to induce

MM tumor cells apoptosis without causing general toxicity in non-transformed cells. Considering
the indispensable role of proteasome function in all cell types this raises an important question:
why is bortezomib particularly toxic to MM cells? First, proteasome inhibition stabilizes the NF-κB
complex in the cytoplasm and reduces NF-κB dependent gene expression. MM cells have
increased NF-κB activity and rely on this pathway for survival and proliferation

200.

Furthermore,

NF-κB activity generates more pro-inflammatory NF-κB activators in a positive feedback loop,
therefore partial proteasome inhibition is sufficient to reduce this pathological cascade

201.

Bortezomib-mediated NF-κB inhibition enhances the anti-MM conventional chemotherapeutic
agents (e.g. dexamethasone, lenalidomide) effects and increases MM patient progression-free
survival (PFS) and overall survival (OS)

151.

Second, proteasome inhibition reduces misfolded

protein clearance. MM arises from mature immunoglobulin (Ig)-secreting plasma cell hyper
proliferation in the bone marrow and MM cells have a high rate of Ig production. Immunoglobulins
are large multisubunit molecules synthesized and folded in the ER where they are post-
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translationally modified prior to secretion. The high Ig production rate and multiple modifications
make MM cells heavily reliant on the proteasome and ERAD to maintain ER homeostasis 202 – so
it reasons they will be more sensitive to proteasome inhibition. Accordingly, treatment of MM cells
with proteasome inhibitors results in a toxic misfolded protein buildup activating JNK and
eventually resulting in apoptosis. Third, proteasome inhibition stabilizes various tumor suppressor
proteins (e.g. p27, p53) and prevent cell cycle progression 203.
IV.A.2. Bortezomib Resistance. Although bortezomib revolutionized the treatment for MM,
bortezomib resistance and relapse often occurs in patients who initially respond to bortezomib.
Therefore, bortezomib resistance is a major issue for MM therapy. There are several mechanisms
linked to bortezomib resistance and they fall into two broad categories. First, there are changes
in proteasome subunit composition and expression

204.

Additionally, mutations in the β5

bortezomib binding pocket are associated with bortezomib resistance in MM cell lines

205.

However, the same mutations have not been confirmed in MM patients resistant to bortezomib
treatment. Bortezomib-resistant MM cells also display transcriptome alterations including
increased anti-apoptotic protein and decreased pro-apoptotic protein expression 206. For example,
bortezomib-resistant MM cells have higher Bcl-2 family

207,

and heat shock protein (Hsp27,

Hsp70, and Hsp90) expression, which are expected to mitigate the misfolded protein burden in
these cells.
Other extrinsic factors contribute to bortezomib-resistance. Not surprisingly, the bone marrow
microenvironment plays an important role in supporting bortezomib-resistance. Bone marrow
stem cells (BMSC) isolated from bortezomib-resistance MM patients have different cytokine
profiles than BMSCs from bortezomib-sensitive MM patients

208.

Several specific pro-survival

cytokines and microRNAs are upregulated and contribute to bortezomib-resistance

209.

Interestingly, bortezomib-resistant patient BMSCs confer resistance to proteasome inhibitor naïve MM cells, whereas proteasome inhibitor -naïve MM cells co-cultured with bortezomib-
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sensitive MM patient BSMCs respond to subsequent bortezomib exposure 209. Elucidating specific
microenvironment mechanisms supporting bortezomib-resistance is expected to identify
additional targets for combination therapies to enhance proteasome inhibitor sensitivity in RRMM
patient.
IV.A.3. Bortezomib Dose Limiting Toxicity. The primary dose limiting bortezomib treatment
toxicity is peripheral neuropathy (PN). Bortezomib induced PN typically affects the peripheral
nervous system sensory fibers and is associated with a painful burning sensation, numbness,
and/or tingling in the extremities. Clinical trials report bortezomib-induced PN incidence (all
grades) between 30-60% 210 and grade ≥3 occurring between 2-23% 211. PN is a major cause of
dose reduction or discontinuation in patients and overcoming this limitation is a significant
challenge to clinicians and pharmaceutical development. Recent clinical trials demonstrated that
patients receiving alternative dosing schedules (i.e. once weekly, instead of bi-weekly) or
subcutaneous injection of bortezomib (instead of IV) had a lower incidence of PN, without
changes in efficacy. For patients with intolerable PN, these options constitute another avenue of
hope before discontinuing treatment 211.
Although the exact molecular mechanisms by which bortezomib induces PN are not completely
clear, clinical and experimental evidence points to pathology in the primary sensory neurons cell
bodies as a major contributing factor. The peripheral nervous system (PNS) encompasses the
nerve fibers and cell bodies that reside outside the central nervous system (CNS, i.e. brain and
spinal cord). Sensory receptors in periphery tissues transduce physical stimuli (e.g. pain, touch,
pressure, temperature) into action potentials which are transmitted via primary sensory neurons
to the CNS. The primary sensory neuron cell bodies are in the dorsal root ganglion (DRG) just
outside of the spinal cord. Many in vivo mouse studies and in vitro DRG explant studies of
bortezomib induced PN demonstrate accumulation of ubiquitinated proteins in DRG soma,
defects in mitochondrial calcium homeostasis, disrupted mitochondrial axonal transport,
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alterations in tubulin polymerization and localization, and defects in fast axonal transport due to
blockage of axonal protein turnover

212–214.

Why are the DRG neurons especially susceptible to proteasome inhibitor toxicity? Proper CNS
and PNS neural function requires an exquisitely controlled microenvironment. To this end, the
blood–neural barrier (BNB) and the blood–brain barrier (BBB) form a protective barrier between
the changing circulatory milieu and the PNS and CNS, respectively. These intricate barriers
contain complex tight junction proteins. Unlike the rest of the nervous system, the cell body-rich
area within the DRG has endothelial fenestrations and lacks tight junction proteins, rendering it
more permeable to substances in the blood compared to the rest of the nervous system. This
region is highly vascularized and blood permeability has been observed in human subjects using
magnetic resonance imaging (MRI) with gadolinium contrast agents 210. While bortezomib cannot
cross the tight BNB and BBB, it can cross into the cell body-rich region of the DRG and inhibit
proteasome function. This differential permeability is thought to underlie peripheral sensory
system vulnerability to cytostatic agents used in chemotherapy (e.g. bortezomib) compared with
other neurons in the CNS 210.
Arastu-Kapur et al. (2011) suggest bortezomib induced neurotoxicity is due to mitochondrial
serine protease, HtrA2/Omi, inhibition and independent of proteasome inhibition

215.

They also

showed that a second-generation proteasome inhibitor, carfilzomib, did not inhibit HtrA2/Omi in
this study. The authors conclude that proteasome inhibitor induced neurotoxicity is due to offtarget bortezomib effects, and not generalizable to the proteasome inhibitor class. However, two
subsequent independent studies failed to show bortezomib-mediated HtrA2 inhibition

216,217.

Carfilzomib is associated with less severe PN than bortezomib, however, the role of HtrA2 or
other off target effects in proteasome inhibitor induced PN remains to be determined.
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IV.A.4. Bortezomib Efficacy in Solid Tumors. Despite bortezomib’s clinical efficacy in treating
hematological malignancies, it has had limited success in clinical trials for solid tumors. This may
arise from poor bortezomib tissue penetration (at the doses used in MM) and rapid clearance from
the blood 218. Dosage cannot be increased to overcome poor tissue penetration due to increased
risk for PN. Second generation proteasome inhibitor are in development to overcome these
limitations of bortezomib. Ongoing clinical trials are evaluating combinations of chemotherapy and
radiotherapy with bortezomib in a search for new synergistic drug combinations.
IV.B. Second Generation proteasome inhibitors
Bortezomib treatment efficacy in human cancer renewed interest in developing other novel
proteasome inhibitors to overcome bortezomib limitations. Two second generation proteasome
inhibitors, carfilzomib (2012) and ixazomib (2015), are FDA approved for relapsed-refractory MM
patients. Carfilzomib and ixazomib are well tolerated in heavily pretreated patients and show
effectiveness in bortezomib-resistant cases

211.

Importantly, most cases of PN with carfilzomib

and ixazomib are low grade and usually do not worsen preexisting PN resultant from previous
bortezomib treatment

211.

Schlafer et al. (2017) provide a detailed review of the bortezomib,

carfilzomib, and ixazomib clinical trials. Here we highlight second-generation FDA approved PIs
and selected newer PIs undergoing preclinical evaluation in hematological cancers, solid tumors,
and autoimmune disorders208. Our list of proteasome inhibitors is not intended to be
comprehensive, but to rather increase familiarity with these important aspects. Table 4 lists
important properties of first- and second-generation proteasome inhibitors in clinical trials.
IV.B.1. Carfilzomib. Carfilzomib (Kyprolis®) is the second FDA approved proteasome inhibitor.
Carfilzomib is used as a single agent or in combination with immunomodulatory agents in RRMM
patients who have received one to three prior therapies, including other proteasome inhibitors 219.
Carfilzomib has a tripeptide backbone containing phenylalanine, leucine, and homophenylalanine
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with a terminal epoxyketone group that forms an irreversible covalently bond with the proteasome
catalytic threonine

220.

As with epoxomicin, the carfilzomib epoxyketone warhead forms a dual

covalent adduct with the active site threonine, which greatly reduces the off targets.
Importantly, carfilzomib provides some therapeutic benefit for RRMM patients who relapse after
bortezomib treatment, while also rendering less neurotoxic side effects

211,219.

The ENDEAVOR

phase III clinical trial compared bortezomib plus dexamethasone versus carfilzomib plus
dexamethasone in a cohort of newly diagnosed MM patients. ENDEAVOR reported significantly
higher incidence of ≥2 PN in the bortezomib group (32%) vs. 6% in the carfilzomib group 221. This
was the first head to head comparison between bortezomib and carfilzomib patients.
Unfortunately, drug resistance is observed following carfilzomib treatment in a small subset of
patients

222.

Although the resistance mechanism is not fully elucidated, studies suggest that

increased expression of drug efflux pump P-glycoprotein (P-gp, a known transporter of
carfilzomib) in carfilzomib-resistant cells contributes to the resistant phenotype 223. However, more
detailed studies are needed to confirm this resistance mechanism.
Carfilzomib also shows therapeutic promise in several preclinical models of solid tumors.
Carfilzomib effectively sensitized tumor cells to doxorubicin induced apoptosis in several in vivo
preclinical solid tumor models including neuroblastoma and colon cancer 224,225. Many doxorubicin
(dox) resistant tumor cells have upregulated NF-κB activity that promotes survival

226,227,
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suggesting combination treatment with a proteasome inhibitor may be effective at overcoming
dox resistance. Although the exact mechanisms are unknown, it is thought that carfilzomibmediated NF-κB inhibition sensitizes tumor cells to doxorubicin. Based on these preclinical
studies, carfilzomib (in combination with other chemotherapy drugs) is currently undergoing phase
I and II clinical trials in advanced solid tumors, renal disease, transplant rejection, and
hematological malignancies (clinicaltrials.gov).
IV.B.2. Ixazomib. Bortezomib and carfilzomib are administered intravenously, requiring patients
to visit a clinic several times over the course of their treatment. Ixazomib (MLN9708, Ninlaro®) is
the first and only orally bioavailable PI FDA approved for RRMM treatment

228.

Ixazomib was

developed through a large-scale boron-containing PI screening for compounds with
physiochemical properties distinct from bortezomib. Ixazomib is a bioavailable prodrug which is
hydrolyzed into the active metabolite MLN2238 when exposed to the GI tract and plasma and is
a potent and reversible β5 proteasome subunit inhibitor 229.
Despite similarities, there are important distinctions between ixazomib and bortezomib.
Importantly, clinical trials report a lower incidence of PN in patients treated with ixazomib
compared to bortezomib, and ixazomib is effective in treating bortezomib-resistant RRMM
patients

230.

In addition, ixazomib demonstrated five times higher drug distribution supported by

blood volume distribution (Vd), with a Vd 20.2 L/kg for ixazomib vs. Vd =4.3 L/kg for bortezomib
229.

Ixazomib also displays anti-tumor efficacy in solid tumor preclinical models

224.

Numerous

phase I and II clinical trials are underway, evaluating ixazomib treatment in glioblastomas, solid
tumors, triple negative breast cancer, B cell lymphoma, lupus, bladder cancer, and lymphoma.
IV.C. Additional proteasome inhibitors in clinical trials.
IV.C.1. Marizomib. Marizomib (NPI-0052, Salinosporamide A) is a naturally occurring PI isolated
from the marine actinomycete Salinispora tropica and is under development for MM and
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glioblastoma (GBM) treatment 231. Marizomib is a γ-lactam-β-lactone which demonstrates unique
binding and bioavailability profiles, setting it apart from other PIs. Its unusual binding mechanism
was elucidated using biochemical and crystallography approaches. In contrast to other βlactones, marizomib has unique chloroethyl and cyclohex-2-enylcarbinol substituents, giving rise
to important interactions within proteasome active sites. These unique interactions are thought to
be responsible for marizomib's high proteasome affinity and specificity 64.
Marizomib irreversibly inhibits β5 (IC50 3.5 nM) and β2 (IC50 28 nM) active sites, although it can
inhibit β1 at higher concentrations (IC50 430 nM) 232. In vitro and binding competition experiments
show marizomib binds to all three subunits at clinically relevant doses 229. Unexpectedly, patient’s
β1 and β2 activities were not affected (in PBMCs) during the first cycle of marizomib treatment
233.

After the second dose cycle, decreased peptidase was observed, but only in packed whole

blood samples – which contain mostly erythrocytes

233.

Whether marizomib inhibits β1 and β2

activity in nucleated cells that can synthesize new proteins remains to be determined. Importantly,
marizomib shows the ability to overcome bortezomib and carfilzomib resistance in a limited
number of RRMM patients 233. Additional trials investigating marizomib in combination with other
chemotherapy drugs in RRMM are ongoing.
Marizomib is the only PI in clinical trials that can permeate the blood brain barrier, making it an
attractive candidate in CNS malignancy treatment. In animal studies, marizomib distributed to the
brain at 30% blood levels in rats and significantly inhibited (>30%) baseline chymotrypsin-like
proteasome activity in monkey brain tissue

234.

Furthermore, marizomib treatment elicited a

significant antitumor effect in a rodent intracranial malignant glioma model

234

and was well

tolerated in phase I/II clinical trials for advanced and newly diagnosed glioblastoma. Based on
encouraging results from phase I and phase II marizomib trials in GBM patients, a phase III trial
of marizomib in combination with standard temozolomide-based radiochemotherapy for patients
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with newly diagnosed GBM (clinical trial NCT033450951) is scheduled to begin June 2018. GBM
is the most common high-grade brain malignancy in adults with a 25% two-year survival after
standard treatment 235. New therapies are critically needed for these patients.
IV.C.2. Oprozomib. Efforts to synthesize an orally bioavailable epoxyketone proteasome inhibitor
led to oprozomib (PR-047, ONX-0912) development. Oprozomib is an irreversible and potent β5c
and β5i proteasome subunit inhibitor, with an IC50 36 nM and 82 nM, respectively 236. Oprozomib
oral administration demonstrated anti-tumor activity in MM, squamous cell carcinoma of the head
and neck, and colorectal cancer preclinical models

237.

The first phase I study (NCT01365559) with single-agent oprozomib evaluated patients with
advanced solid tumors. Oprozomib was well tolerated, with low-grade gastrointestinal side effects
being the most common. Unfortunately, despite dose-dependent increases in proteasome
inhibition, the best response achieved was stable disease (23% of patients) and no clinically
meaningful correlates between proteasome inhibition and treatment efficacy were observed.
Considering this was a heavily pretreated patient population with advanced cancer, the lack of a
therapeutic response does not necessarily reflect the potential of oprozomib to treat earlier stages
or other cancers. Clinical studies investigating the oprozomib efficacy in hematological
malignancies are ongoing. In a phase I/II study (NCT014164282), a new oral oprozomib
formulation is being investigated, and other studies are investigating oprozomib in combination
with dexamethasone and lenalidomide.
IV.D. Immunoproteasome specific proteasome inhibitors
Specifically targeting the immunoproteasome could be advantageous over currently approved PIs
in treating certain diseases. The immunoproteasome is present at low levels in normal cells. In

1 ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2017 Nov 17 -. Identifier NCT03345095

2

ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2011 Aug 5 -. Identifier NCT01416428
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contrast, some cancers (including MM), inflammatory diseases, and autoimmune diseases have
increased immunoproteasome subunit expression

238.

It is thought that selective

immunoproteasome inhibition may have less adverse effects than broadly acting PIs like
bortezomib and carfilzomib since certain cell populations would be preferentially affected 239.
IV.D.1. ONX-0914. ONX-0914 (PR-957) is an irreversible epoxyketone β5i immunoproteasome
subunit inhibitor, with minimal cross-reactivity for the constitutive proteasome β5 subunit (β5c).
Preclinical trials demonstrate β5i inhibition with ONX-0914 attenuates disease progression in
colorectal cancer
242.

240,

rheumatoid arthritis

241,

and systemic lupus erythematosus animal models

Importantly, ONX-0914 displays low neurotoxicity without sacrificing efficacy, an effect that

may be attributed to the selective β5i inhibition

243.

Johnson et al. (2017) synthesized and

screened ONX-0914 analogues for β2i inhibition. They identified and characterized compound
KZR-504, a β2i selective proteasome inhibitor. However, KZR-504 displayed poor membrane
permeability and did not ameliorate cytokine release from stimulated splenocytes

244.

Another analogue, KZR-616, was well tolerated in a phase I clinical trial in healthy volunteers with
minimal adverse side effects (Lickliter et al., 20173). KZR‐616 recently entered a phase Ib/II
clinical trial (NCT033930134) as a single agent treatment for autoimmune‐triggered inflammation
(systemic lupus erythematosus).
IV.E. Novel combination therapies
Anti-cancer drugs are often administered in combination to synergistically enhance cytotoxicity
and prevent drug-resistant tumor cell population development. Several known chemotherapy
resistance mechanisms result from abrogated proteasome activity. For example, NF-κB activity

3

Lickliter J, Anderl J, Kirk CJ, Wang J, Bomba D. KZR-616, a Selective Inhibitor of the Immunoproteasome, Shows a Promising Safety and Target Inhibition
Profile in a Phase I, Double-Blind, Single (SAD) and Multiple Ascending Dose (MAD) Study in Healthy Volunteers[abstract].ArthritisRheumatol. 2017; 69(suppl 10
4
ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2018 Jan 8 -. Identifier NCT03393013
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is upregulated in solid tumors that develop chemotherapy (e.g. doxorubicin) or radiation
resistance and is a driving force behind the resistant phenotype 51. Accordingly, preclinical studies
with solid-tumor xenograft and cellular models show increased sensitivity to chemotherapy and/or
radiation induced apoptosis when combined with proteasome inhibitors

245.

Several phase I and

II clinical trials are evaluating PI safety and efficacy in combination with various chemotherapy
agents in recurrent or refractory advanced cancers.
β1 and β2 site upregulation has been reported in tumor cells resistant to bortezomib or carfilzomib
treatment 51. LU-102 is a peptide vinyl-sulfone β2 specific inhibitor

246

and alone it is toxic to MM

cells, but it also synergized with β5 inhibitors (bortezomib and carfilzomib) to overcome PI
resistance in MM cell lines 246. The observed synergy between β5 and β2 inhibitors suggests that
multiple site-specific proteasome inhibitor combinations may be an effective alternative in PIresistant malignancies with reduced risk of adverse side effects.
V. Novel Proteasome Drug Targets
V.A. Deubiquitinating enzyme inhibitors
With three ubiquitin receptors on the proteasome, several shuttling factors, and multiple ubiquitin
chain types on substrates, the process of substrate recognition by the 26S proteasome is
incredibly complex and much remains unknown. We briefly summarized the process of ubiquitindegradation in Part I and here, will discuss how deubiquitinating enzymes (DUBs) may be
targeted to treat diseases. Detailed reviews of 26S substrate recognition and processing have
already been written 77 and 76.
Three DUBs are associated with the 26S proteasome: Rpn11, Uch37 and Usp14. Rpn11 is the
only DUB that is an integral part of the 19S regulatory particle. Positioned directly above the
translocation pore, Rpn11 is a metalloprotease that removes Ub chains at their attachment point
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(lysine) on the substrate that is committed for degradation

75.

Mutations in Rpn11 that disrupt its

catalytic activity stall ubiquitin substrate degradation and eventually lead to cell death 247. Li et al.
(2017) recently developed capzimin, a first-in-class selective inhibitor of Rpn11. The Rpn11 active
site is located within the highly conserved JAMM motif and features a catalytic Zn2+ ion
Capzimin binds the catalytic zinc ion and prevents Rpn11 activity

248.

247.

Remarkably, Capzimin

treatment stabilized proteasome substrates and blocked proliferation in several tumor cell lines
248.

This anti-tumor activity suggests Rpn11 inhibition may be an effective alternative to active site

inhibition for treating malignancies. Unlike Rpn11, Uch37 and Usp14 are only transiently
associated with the 19S regulatory particle

166,249.

Uch37 and Usp14 enzymes trim Ub chains

before the substrate is committed to degradation, which may suppress protein degradation by
promoting early substrate release

76.

Accordingly, loss of Usp14 homologue Ubp6 increases

substrate degradation by the proteasome

250,251.

Despite high affinity, Usp14 easily dissociates

from 26S complexes during conventional proteasome purification techniques and should be
considered when designing in vitro experiments

76.

Enhancing proteasome function has the potential to treat protein misfolding disorders, such as
neurodegenerative diseases, and Usp14 inhibition may promote ubiquitin-dependent protein
degradation. To this end, Boselli et al. (2017) developed IU-47, a potent and specific inhibitor of
Usp14. Inhibition of Usp14 DUB activity by IU-47 promoted proteasome degradation of the
microtubule associated protein tau (implicated in the pathogenesis of Alzheimer’s disease) in
neuronal cultures and enhanced resistance to oxidative stress

252.

The implications of

pharmacological proteasome activation will be discussed in the following section.
V.B. Activation of the 20S by gate-opening
We highlighted essential functions of the proteasome required for proper neuronal functioning in
Part I. Then Part II discussed the negative impacts of proteasome inhibition on primary sensory
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neurons. To bridge these concepts, we will further discuss evidence that supports the proteasome
as a target for pharmacological activation to treat proteopathies.
The most common neurodegenerative diseases are characterized by an accumulation of
aggregation-prone proteins concomitant with a loss of proteostasis, which results in progressive
death of neurons

121–123.

Impaired proteasome function has been implicated, as a primary cause

or a secondary consequence, in the pathogenesis of many neurodegenerative diseases, including
Alzheimer’s, Parkinson’s, and Huntington’s disease 47,124–127.
Soluble forms of aggregated proteins, called oligomers, are implicated in the pathogenesis of
most neurodegenerative diseases
255–260.

253,254

and haven been shown to impair proteasome function

Our lab recently identified a mechanism in which soluble oligomers of different proteins

from multiple neurodegenerative diseases allosterically impair the proteasome gate by a shared
mechanism

175.

These toxic oligomers shared a similar three-dimensional conformation

recognized by the anti-oligomer antibody, A11

261.

The A11+ oligomers bound to the outside of

the 20S cylinder and stabilized the gate in the closed conformation. However, proteasome
function could be rescued by adding an 8 residue HbYX peptides. The HbYX peptides
allosterically open the gate and the HbYX motif peptides overcame the oligomer inhibition and
restored proteasome function 175.
A recent and popular idea for treating neurodegenerative diseases is enhancing proteasome
activity to suppress toxicity and related proteotoxic pathophysiology, but to date no drugs are
available that directly activate proteasome function.
Since IU-47 exerts its effect upstream of the proteasome gate, it is not expected to function in
conditions where the proteasome gate is impaired. Choi et al. (2016) generated a HEK293 cell
line with a stable transfection of a mutant 20S α-subunit (α3∆N) that induces 20S gate opening.
They showed that HEK293-α3∆N cells had increased degradation of proteasome substrates
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(including tau protein) and increased resistance to oxidative stress compared to WT

171.

While

serving as a proof-of-principle that opening the proteasome gate can clear aggregation prone
proteins and increase cell viability, it cannot be determined if pharmacologically activating the
proteasome in an already diseased state (pre-existing oligomers, aggregates, and oxidative
stress) can restore cellular proteostasis. Nonetheless, elucidation of a common mechanisms of
proteasome inhibition is a major step towards the rational design of proteasome activating
compounds, which may be a promising route to restore proteostasis in diseases.
Conclusions
As a highly regulated, multicatalytic macromolecular complex, the proteasome possesses
multiple drug targets to module its degradation capacity. Proteasome inhibitors helped early
researchers study the proteasome’s cellular functions. Today, three inhibitors are approved for
use in the clinic to treat hematological cancers and several more inhibitors (synthetic and
naturally occurring) are in preclinical and clinical testing. Fine tuning the pharmacological
properties of proteasome inhibitors may improve their efficacy for use in solid tumors. The last
decade has witnessed major progress in our understanding of 26S proteasome structure and
dynamics. In the coming years, we expect development of new inhibitors and activators of nonproteolytic components of the 26S proteasome. We anticipate that proteasome activation will
become a validated target to treat proteotoxic diseases.
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Abstract
Protein accumulation and aggregation with a concomitant loss of proteostasis contributes to the
vast majority of neurodegenerative diseases. Because the ubiquitin-proteasome system (UPS)
plays a major role in protein degradation and proteostasis we hypothesized that a general mechanism of UPS impairment could contribute to neurodegenerative diseases. Here, we show that
three different proteins from Alzheimer’s, Parkinson’s, and Huntington’s disease that misfold and
oligomerize into a shared three-dimensional structure potently impair the proteasome. This study
indicates that the shared conformation allows these oligomers to bind to and inhibit the proteasome with low nM affinity, impairing ubiquitin-dependent and ubiquitin-independent proteasome function in brain lysates. Detailed mechanistic analysis demonstrates that these oligomers inhibit the 20S proteasome through allosteric impairment of the substrate-gate in the 20S
core particle, preventing the 19S regulatory particle from injecting substrates into the degradation
chamber. These results provide a novel molecular model for oligomer-driven impairment of proteasome function that is relevant to a variety of neurodegenerative diseases, irrespective of the
specific misfolded protein that is involved.
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Introduction
The most common neurodegenerative diseases are characterized by an accumulation of aggregation-prone proteins concomitant with a loss of proteostasis, that results in progressive death of
neurons1–3. Culminating evidence from the past two decades has revealed that soluble, oligomeric
forms of protein aggregates (such as A in Alzheimer’s disease, -Synuclein in Parkinson’s disease, and mutant huntingtin in Huntington’s disease) are likely the most toxic species 4,5. While
different regions of the brain are affected in these distinct diseases, proteotoxicity is a shared
feature found in these affected regions of the brain. This suggests that a common mechanism of
proteotoxicity could contribute to the development and progression of these distinct neurodegenerative diseases.
Proteostasis6,7 is maintained by several systems in the cell including the ubiquitin-proteasome
system (UPS), chaperones, chaperone-mediated autophagy, and macroautophagy8. The ubiquitin proteasome system (UPS) is the principle route for the degradation of intracellular misfolded,
damaged, or unneeded proteins9. If the efficiency of proteostasis systems declines, misfolded
proteins accumulate and aggregate in the cell, which can disrupt normal cellular functions and
even cause cell death10. Maintaining proteostasis is especially important for neurons due to their
complex architecture, long lifespan, and inability to dilute aggregate load by cell division11. Most
importantly, the UPS is critical for normal functioning of neuronal synapses, including synaptic
protein turnover, plasticity, and long-term memory formation, which rely on tightly controlled
changes in the proteome11–15. Recently, Ramachandran & Margolis (2017)16 identified a mammalian nervous-system-specific membrane proteasome complex that directly and rapidly modulates
neuronal function by degrading intracellular proteins into extracellular peptides that stimulate neuronal signaling through postsynaptic N-methyl-D-aspartate receptors.
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Decreased proteasome function has been reported in a broad array of chronic neurodegenerative
diseases17. Impaired proteasome function has been implicated, as a primary cause or a secondary consequence, in the in the pathogenesis of many neurodegenerative diseases, including Alzheimer’s, Parkinson’s, and Huntington’s diseases2,17–21. In fact, brain region-specific proteasome
inhibition (e.g. forebrain, substantia nigra) closely mirrors the neuropathology and clinical hallmarks of neurodegenerative diseases22–26. A small percentage of neurodegenerative disease are
caused by hereditary gene mutations, many of which affect components of the UPS (e.g. PARK1,
PINK)20. However, the vast majority of neurodegeneration is idiopathic in origin and the involvement of the UPS is less clear17. What is clear in these diseases is that proteins that are normally
degraded are not properly degraded after misfolding occurs, leading to their accumulation. Several groups have provided evidence that aggregated proteins from neurodegenerative diseases
interact with and impair proteasome function27–37. However, it is not clear what specific types of
aggregates impair the proteasome, and a mechanistic understanding of how they do so has not
been elucidated. One study has been able to show that heterogeneous aggregates of the mouse
prion protein, PrPsc, reduced substrate entry by decreasing proteasomal gating36. Despite these
many efforts, an understanding of why and how the proteasome is so generally impaired in neurodegenerative disease has remained elusive. Understanding the mechanism of impairment will
provide a basis for drug development to restore proteasome activity and proteostasis in the brain
and is therefore an important effort.
Proteins targeted for proteasomal degradation are marked by the attachment of several ubiquitin
proteins. These poly-ubiquitinated substrates are recognized by the 26S proteasome and are
degraded9. The 26S proteasome is made up of a 20S proteasome core particle capped on one
or both ends by the 19S regulatory particle. It degrades proteins by a multistep process: the 19S
regulatory particle binds ubiquitinated substrates and opens a substrate entry gate in the 20S38–
40

and unfolds its substrates by translocating them into the 20S catalytic chamber where they are
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degraded41,42. The 20S is a hollow cylindrical complex composed of four heteroheptameric rings
arranged in a 7-7-7-7 fashion43. Proteolysis occurs on the interior surface of -subunit rings.
The substrate gate is formed by the N-termini of the -subunits, which prevent unregulated access
to the catalytic sites by folding over the entry pore and blocking substrate translocation into the
catalytic chamber44. Triggering of gate-opening by the 19S requires the C-terminal HbYX motif of
the 19S ATPases to bind to intersubunit pockets (between the -subunits) on top of the 20S45.
The HbYX motif allows the 19S to bind to the 20S core particle, but binding of the HbYX motif by
itself (as a hepta-peptide) is also sufficient to allosterically induce conformational changes in the
-subunits that cause gate opening45–48. Clearly, regulation of the 20S proteasome gate is an
important aspect of proteasome function and the cell has evolved many different proteasomal
regulators that control 20S gate-opening, many of which contain the HbYX motif (e.g. the 19S
ATPases: Rpt2, Rpt3, Rpt5; Blm10/PA200; Pba1-Pba2; PI31; and archaeal CDC48/P97), and
some that do not (i.e. the 11S family: PA28 and PA26)48.
This study demonstrates that misfolded proteins from three distinct neurodegenerative diseases
adopt a common three-dimensional conformation that is capable of impairing ubiquitin-dependent
and ubiquitin-independent proteasome function. Although these oligomers possess unique primary sequences, they all impair the proteasome through allosteric stabilization of the closed gated
conformation of the 20S core particle, therein blocking protein degradation. Moreover, these toxic
oligomers specifically impair HbYX motif dependent gate-opening, yet do not impair gate-opening
induced by the 11S family of regulators. These data suggest that proteasome impairment in various neurodegenerative diseases may share a common mechanism.
Results
Prior studies report conflicting observations regarding the impairment of the proteasome by disease-related aggregated proteins, some demonstrating proteasome impairment27–30,32–35 while
others do not49,50. The major limitation of these studies is that the conformational state of the
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aggregates was not accounted for or considered. Aggregation-prone proteins have the unique
property of conformational polymorphism. During amyloid formation a variety of aggregate species are formed, ranging from small dimers up to large insoluble fibrils. Oligomers are metastable
intermediates to fibril formation or an off-pathway product of aggregation and are recognized as
the primary pathogenic effectors51. Since the previous studies used heterogeneous compositions
of the aggregated proteins, these seemingly conflicting results for proteasome impairment are not
surprising. In this study, we purify to homogeneity a specific conformation of a pathological oligomer, identified its conformational status, and extensively characterize its mechanism of impairment on human and mammalian 20S/26S proteasomes. In addition, this study identifies a specific
oligomeric conformation found in Alzheimer’s, Parkinson’s, and Huntington’s disease that substantially impairs proteasome function in a way that could contribute to the development and progression of these and other neurodegenerative diseases.
To determine if specific types of oligomers are responsible for proteasome impairment we began
by generating various mixed populations of protein aggregates made from either amyloid- 1-42
(A), -synuclein (-Syn), or huntingtin exon 1 with a polyQ-expansion (Htt-53Q) and asked if
they could impair purified mammalian 20S proteasome. We found that under specific oligomerization conditions (different for each protein type) each of the aggregate preparations could significantly impair the 20S proteasomes ability to hydrolyze fluorogenic peptide substrates (Fig. 1A).
These results replicate those which have been reported to some extent previously29–31. Next, we
separated the mixed aggregates into soluble and insoluble fractions and again tested their effect
on proteasome activity. The soluble oligomers, but not equal amounts of monomers or insoluble
fibrils, strongly impaired proteasome activity (Fig. 1B) in a concentration-dependent manner (Supplementary Fig. 1). The eukaryotic proteasome has three types of active sites, each displaying
preference for cleavage after specific residues (chymotrypsin-like, hydrophobic; caspase-like,
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acidic; trypsin-like, basic). Substrate hydrolysis by all three of the catalytic sites were impaired by
the soluble oligomers (Supplementary Fig. 2).

***

***

***

ns

*

Figure 1. A specific conformation of soluble oligomers potently inhibits the mammalian 20S proteasome. (a) Mammalian
20S proteasomes were incubated with mixed aggregates of A1-42 (5M), -Syn (1M), Htt-53Q (0.1M), or an equal volume of
oligomer buffer (control). Proteasome activity (linear rate of LLVY-amc hydrolysis) is represented as a percentage of activity
compared to the control. (b) Crude aggregates from A were separated into soluble and insoluble aggregates (schematic, left) and
were assayed as in A (bar graph, right). For huntingtin monomers, Htt-20Q monomers were used because pure Htt-53Q monomers could not be obtained due to rapid oligomerization. Dot blots of monomers, soluble aggregates, and insoluble aggregates
from B were probed with the conformation-dependent anti-oligomer ‘A11’ antibody (bottom right). (c) Soluble A aggregates from
B were separated by size exclusion chromatography (SEC) (Abs 280nm, solid blue line). 2l from each fraction was evaluated for
its effect on 20S proteasome chymotrypsin-like activity (bars) and probed for anti-oligomer A11 reactivity (dot blot, bottom). (d)
Proteasome activity with up to 5M of A oligomers (A-iO) or A protofibrils (A-PF) from C. (e) Intermediate oligomers from D
were pre-incubated with anti-oligomer A11 antibody (A-iO + A11) or an equal volume of antibody buffer (A-iO) for 30 minutes
at 37°C before to addition to proteasome activity assay. Final concentration of A-iO in the assay was 0.25M (the ~IC50 as
determined in D). The concentrations of aggregates are calculated based on the respective monomeric peptide/protein mass (A,
4.5 kDa; -Syn, 14 kDa; and Htt-53Q, 22 kDa). All controls contained an equal volume of buffer identical to that of the respective
aggregates. Data are representative of three or more independent experiments performed in triplicate. Error bars represent ±
standard deviation. ***p<0.0001; *p<0.05; ns p>0.05 (students t test)
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Supplemental Figure 1. Corresponds to Figure 1B.
A11(+) soluble aggregates of A, -Syn, and Htt-53Q impair the
mammalian 20S proteasome in a concentration-dependent
manner. Mammalian 20S proteasomes were incubated with soluble aggregates of A (a), -Syn (b), or Htt-53Q (c) at the indicated
concentrations and proteasome activity (LLVY-amc hydrolysis) was
measured. A mixed aggregates are the same as used in Figure
1a. Soluble oligomers from -Syn and Htt-53Q are from Figure 1b.
Half-maximal inhibition of the 20S is indicated. The concentrations
of aggregates are calculated based on the respective monomeric
peptide/protein mass (A, 4.5 kDa; -Syn, 14 kDa; and Htt-53Q, 22
kDa). All controls contained an equal volume of buffer identical to
that of the respective aggregates. Data is representative of three
independent experiments performed in triplicate. Error bars represent ± standard deviation. Sigmoidal dose response (variable slope)
line fit performed with GraphPad version 7.
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Supplemental Figure 2. Corresponds to Figure
1B.
A11(+) oligomers from A, -Syn, and Htt-53Q
impair substrates that are specific for all three
proteolytic sites in the mammalian 20S proteasome. Mammalian 20S proteasomes were incubated with A oligomers (2M) (a), -Syn A11+
oligomers (1M) (b), or Htt-53Q A11+ oligomers
(0.1M) (c), and proteasome chymotrypsin-like
(LLVY-amc hydrolysis), caspase-like (nLPnLDamc hydrolysis), and trypsin-like (RLR-amc hydrolysis) activity was measured. Chymotrypsin-like and
caspase-like activity assays used 0.5nM of 20S
proteasome, trypsin-like activity assays used 1nM
of 20S proteasome. The concentrations of aggregates are calculated based on the respective monomeric peptide/protein mass (A, 4.5 kDa; -Syn,
14 kDa; and Htt-53Q, 22 kDa). All controls contained an equal volume of buffer identical to that of
the respective aggregates. Data is representative
of three independent experiments performed in
triplicate. Error bars represent ± standard deviation. ****p<0.0001; ***p<0.001; **p<0.01 (students
t test).
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A, -Syn, and Htt-53Q monomers are relatively unstructured and they can enter the 20S proteasome to be degraded. However, the monomers fail to impair peptide hydrolysis by the proteasome at equal concentrations as the oligomers (Fig. 1B) therefore, substrate competition at
the active site cannot explain impairment by the oligomers. Furthermore, oligomers are too large
(Fig. 2G-H) to enter the 13Å wide substrate-entry channel of the 20S proteasome. Additionally,
since the insoluble aggregates of these proteins cannot impair the proteasome (Fig. 1B), this
suggests that impairment by the oligomers may be due to a specific conformation of the soluble
oligomers which is lost after conversion to larger aggregates or fibrils. This is consistent with
literature that ascribes cellular toxicity to soluble oligomers in neurodegenerative diseases 4,52,53.
Many species of oligomeric structures have been described, and antibodies developed to recognize specific structural conformations of disease related species 54–56. Kayed et al. (2003)55 generated a polyclonal anti-oligomer antibody (A11) that specifically recognizes some types of protein
oligomers independent of the proteins amino acid sequence. This A11 antibody recognizes some
oligomeric species of A, polyglutamine proteins, -synuclein, and prion, and has been used to
assess the presence of oligomers in diseased brains compared to aged matched controls55,57. We
performed a dot blot with A11 on the monomers, oligomers, and insoluble fibrils for each protein
that we tested. All three of the soluble oligomer preparations contained the A11 epitope (A11+),
while the epitope was absent in the monomeric and fibril fractions (Fig. 1B bottom).
It is interesting that all three soluble oligomer types that impaired proteasome activity also showed
strong A11 antibody binding. To correlate proteasome impairment with the presence of the A11
epitope more specifically, the soluble fraction of the A aggregates were separated by size exclusion chromatography. Three prominent populations of soluble aggregates were observed, one in
the void volume consistent with larger protofibrils (A-PF), a second peak corresponding to intermediate sized oligomers (A-iO) and a third pool of small oligomers and monomers (Fig. 1Cchromatogram). The effect of each fraction on 20S proteasome activity was determined. Only the
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intermediate sized oligomers (~56kDa) impaired the 20S proteasome (Fig. 1C bars) and this impairment correlated with the fractions that were positive for A11 (Fig. 1C dot blot). This inhibitory
species also impaired the degradation of fluorogenic substrates specific for each of the 20S’s
three different proteolytic sites as observed in the mixed oligomer populations (Supplementary
Fig. 3A). This suggests that impairment could be due to impairment of substrate entry rather than
impairment of a specific catalytic active site. The A protofibril peak (A-PF), lacking the A11
epitope, did not impair degradation of any fluorogenic substrates, even in the presence of ten
times more A protofibrils than A intermediate oligomers (Fig. 1D & Supplementary Fig. 3B).
Supplemental Figure 3. Corresponds to
Figure 1C.
A11(+) A intermediate oligomers (A-iO)
impair the degradation of substrates specific for each of the three peptidase activities in the 20S, and A11(-) A protofibrils
(A-PF) do not have any effect. Mammalian 20S proteasomes were incubated with
peak A fractions from size exclusion chromatography in Fig. 1D: 2.5M A-iO (a) or
5M A-PF (b). Chymotrypsin-like (LLVYamc hydrolysis, rfu/min) and caspase-like
(nLPnLD-amc hydrolysis, rfu/min) activity
assays used 0.5nM of 20S proteasome, trypsin-like (RLR-amc hydrolysis, rfu/min) activity assays used 2nM of 20S proteasome.
The concentrations of aggregates are calculated based on the monomeric peptide mass
(4.5 kDa). All controls contained an equal
volume of buffer identical to that of the respective aggregates. Data is representative
of three independent experiments performed
in triplicate. Error bars represent ± standard
deviation. ***p<0.0001; **p<0.001(students t
test).
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Supplemental Figure 4. Corresponds to Figure 1C.
Soluble high molecular weight A oligomers also impair the 20S proteasome if they are A11 positive. (a) High molecular
weight A11(+) oligomers of A were separated by size exclusion chromatography, peak fractions (10l) were separated by nativePAGE and coomassie stained (top). Each fraction (2l) was evaluated by slot blot for A11 immunoreactivity (bottom). (b) 20S
proteasome activity (nLPnLD-amc hydrolysis, rfu/min) was determined with fractions from part A (0.5l). The concentrations of
aggregates are calculated based on the monomeric peptide mass (4.5 kDa). All controls contained an equal volume of buffer
identical to that of the respective aggregates. Data is representative of three independent experiments performed in triplicate.
Error bars represent ± standard deviation. ***p<0.0001; **p<0.001; *p<0.05 (students t test).
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It is plausible that proteasome impairment is due to the oligomer size rather than a specific oligomeric structure. To determine if the impairment is due to the size of the oligomer/protofibrils and
whether the shared A11 reactivity is merely a coincidence, we generated high molecular weight
(200-400 kDa) A11+ A oligomers (Supplementary Fig. 4A) and A11+ A-protofibrils (>700 kDa)
(Supplementary Fig. 5A). The high MW A11+ A oligomers impaired the 20S commensurate with
the level of A11 reactivity (Supplementary Fig. 4A & B). The higher molecular weight A11+ A
protofibrils also impaired substrate hydrolysis by all three active sites of the proteasome (Supplementary Fig. 5B), although to a considerably lesser extent than the intermediate A oligomers
(Fig. 1D). This is expected because protofibrils form when oligomers bind to one another to form
a chain of oligomers58, which sterically blocks surfaces on the internal oligomers but not the terminal ones, which could still interact with the proteasome. To further determine if the structural
epitope of the A11 antibody on the intermediate A oligomers is necessary for proteasome impairment we performed a neutralization assay to block the A11 epitope. A11+ oligomers were
incubated with the A11 antibody prior to testing proteasome activity. A oligomers were used at
a concentration of 0.2M, the IC50, as determined in Fig. 1D, so an increase or decrease in pro-
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Supplementary Figure 5. Corresponds to Figure 1C.
A11(+) A protofibrils impair the mammalian 20S proteasome. (a) A11(+) A protofibril preparation was separated by size
exclusion chromatography (Superose 6 GL). The protofibrils eluted in the column void volume, indicating the soluble aggregates
are >700 kDa (top). Equal volumes of each fraction were probed for A11 reactivity (bottom). (b) Mammalian proteasomes were
incubated with A11(+) A protofibrils (2.5M) and the activity of all three active sites was measured by fluorescent substrate
hydrolysis. The concentrations of aggregates are calculated based on the monomeric peptide mass (4.5 kDa). All controls contained an equal volume of buffer identical to that of the respective aggregates. Data is representative of three independent experiments performed in triplicate. Error bars represent ± standard deviation. * = p < 0.05 (student t test).
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teasome activity could be readily observed. Indeed, the A11 antibody when bound to the A oligomers completely rescued proteasome activity (Fig. 1E). As a control, the experiment was repeated with an antibody raised against the N-terminal residues of A (clone NAB228), which did
not rescue proteasome function (Supplementary Fig. 6). This demonstrates that an available oligomer-specific A11 epitope site is necessary for impairment of the proteasome.
Supplementary Figure 6. Corresponds to Figure 1E.

***
****

Incubation with antibody targeted to the A N-terminus (1-8) does not rescue proteasome activity. A intermediate oligomers (A-iO) from Fig. 1D were incubated with
buffer or monoclonal antibody (NAB228, Invitrogen, epitope 1-8 A peptide) for 30
minutes at 37oC and tested for effect on proteasome activity (nLPnLD-amc hydrolysis).
The concentration of oligomers is calculated based on the monomeric peptide mass
(4.5 kDa). Controls contained an equal volume of buffer identical to that of the A oligomers and/or the NAB228 antibody. Data is representative of three independent experiments performed in triplicate. Error bars represent ± standard deviation.
***p<0.0001; ***p>0.001 (students t test).

Generation and characterization of homogenous and stable A11+ A*56 oligomers
Above we described the isolation of a specific proteasomal inhibitory oligomer from a mixed population of oligomers and aggregates. In order to determine the mechanism of impairment we
sought to generate homogenous, stable, and reproducible A11+ oligomers, which could be used
for reliable mechanistic analysis. In contrast to -synuclein and huntingtin aggregates, methods
to generate physiological relevant oligomers from synthetic A peptides have been extensively
developed. Barghorn et al. (2005)59 characterized a highly stable A (1-42) oligomer species
(~dodecamer) which can be prepared in vitro and can be found in the brains of patients with AD.
The relevance of dodecameric A oligomers to disease pathology is established57,60. With some
modifications to the protocol of Barghorn et al., 2005 we generated A*56 oligomers, and purified
them by nondenaturing size exclusion chromatography (Fig. 2A chromatogram). The major peak
corresponds to the intermediate sized A oligomers in Figure 1D. We tested each fraction for
proteasome activity and found the major peak impaired the 20S (Fig. 2A bar graph). The single
symmetric protein peak demonstrates the homogenous nature of the oligomer preparations. Consistent with A*56 oligomers isolated from human brain tissue and cerebrospinal fluid, our A*56
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oligomers are A11+ (Fig. 2A), run at ~56 kDa (Fig. 2B)57, and significantly impair proteasome
activity in a concentration dependent manner (Fig. 2C). Representative real-time fluorogenic substrate hydrolysis data is also shown (Fig 2D).

***

ns

Figure 2. Generation of stabilized A11+ oligomers (A*56) for mechanistic evaluation of proteasome inhibition. (a) Size
exclusion chromatography (Superose 6 GL 10/300) run that was used to generate a pure A*56 oligomer preparation (blue solid
line, left axis), with proteasome activity (amc hydrolysis) from 1l of the corresponding fractions (bars, right axis; as in Fig. 1), and
A11 dot blot (bottom panel). (b) Native-PAGE A*56 peak fraction from “A” followed by western blot using the A11 anti-oligomer
antibody. (c) Proteasome activity (LLVY-amc hydrolysis) with titrating A*56; the IC50 is approx. 0.22M A (4.5 kDa monomeric
mass) or 18 nM A*56 oligomer complexes (56 kDa mass each). (d) Representative raw data of proteasome activity assay
(nLPnLD-amc hydrolysis) with 1.5M A*56 oligomers (data point from C). (e) Change in polarization of FITC labeled-casein
protein (due to cleavage) in the presence of the 20S proteasome, with and without 10M A*56. (f) Rate of FITC-casein degradation (mP/min). (g) Representative negative stain electron microscopy image of purified A*56 oligomers. Scale bar is 25nm.
(h) Representative tapping mode atomic force microscopy topography image of A*56 oligomers. Scale bar is 0.5m. Heat map
for oligomer height is shown on the right. (i) ThT fluorescence of the indicated A preparations. (j-k) Dot blot with A11 antibody
(j) and oligomer native gel electrophoresis visualized by coomassie stain (k) of non-crosslinked and glutaraldehyde crosslinked
(CL) A*56 oligomers before and after 4-week incubation at 4°C. (l) Proteasome activity (nLPnLD-amc hydrolysis) in the presence
of crosslinked and non-crosslinked A*56 oligomers (0.75M). Concentration of A*56 oligomers is calculated based on the mass
of peptide monomer (A, 4.5 kDa). All controls contained an equal volume of buffer identical to that of the respective aggregates.
Proteasome activity was calculated as in Fig 1A. Data is representative of three or more independent experiments performed in
triplicate. Error bars represent ± standard deviation. All following experiments utilize crosslinked A*56 oligomers unless indicated
otherwise. ***p<0.001; ns p>0.05 (students t test),
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Since A*56 can impair 20S peptide substrate degradation, we asked if it could impair protein
degradation as well. The 20S core particle by itself cannot unfold proteins, so we used -casein,
a classical unfolded protein substrate. We used FITC-labeled casein to follow its degradation in
real time using anisotropy, which monitors the tumbling rate of the fluorophore. When FITC-labeled casein is degraded by the proteasome, the tumbling rate of the fluorophore increases, causing a decrease in anisotropy (Fig. 2E 20S+buffer). Similar to peptide substrates, purified A*56
oligomers also impaired proteasome degradation of the FITC-labeled casein protein (Fig. 2E
20S+A*56), demonstrating that A*56 also impairs the degradation of an unfolded protein. We
confirmed that the relevant morphology of these oligomers were consistent with those published
for synthetic and human brain derived oligomers via: native gel electrophoresis57,61 (for MW),
TEM62 (for spherical shape), AFM63,64 (for size), Thioflavin-T staining65 (slight but low staining),
and anti-oligomer immuno-detection57,65 (Fig. 2G-I).
Oligomers are metastable intermediate structures which complicates analysis when consistent
homogeneous preparations are needed for in depth biochemical analysis. To circumvent this issue, we stabilized the A*56 oligomers by crosslinking, which maintained the conformation of the
A11+ epitope for four weeks when stored at 4oC (Fig. 2J) and without crosslinking the A11+
epitope was not as stable over this time period. In addition, the apparent mass of the crosslinked
oligomers was also assessed via Native-PAGE and we found that it was unchanged over the fourweek incubation (Fig. 2K). The crosslinked A*56 oligomers ran slightly faster than the non-crosslinked oligomers as expected59, likely due to stabilization of the crosslinked structure. In contrast,
the non-crosslinked oligomers partially dissociated into smaller oligomers and formed larger oligomers after four weeks (Fig. 2K). Most importantly, crosslinking of the oligomers does not alter
their proteasome impairment activity compared to the non-crosslinked form (Fig. 2L). Together,
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Figure 3. The A11(+) oligomers bind to the 20S proteasome and impair opening of the substrate gate. (a) 20S proteasomes
(0.4g) and pure non-crosslinked A*56 oligomers (1.5g) were incubated separately or together for 30 minutes (37℃), crosslinked
with 1mM glutaraldehyde for 5 minutes, and separated by Native-PAGE (4-8% tris-acetate gel). Total protein was detected by silver
stain (left), and total A was detected by western blot (right). (b-d) The activity of yeast 20S wild-type (WT) and open-gate (3N)
proteasomes was measured for all three proteolytic sites in the presence of A11(+) oligomers from A*56 (B; 2.5M), -Syn (C;
100nM), and Htt-53Q (D; 50nM). Chymotrypsin-like activity was measured by LLVY-amc hydrolysis, trypsin-like activity by RLRamc, and caspase-like by nLPnLD-amc hydrolysis. The concentrations of aggregates are calculated based on the respective monomeric peptide/protein mass. All controls contained an equal volume of buffer identical to that of the respective aggregates. Data is
representative of three or more independent experiments performed in triplicate. Error bars represent ± standard deviation.
****p<0.0001; ***p<0.001; **p<0.01; *p<0.05; ns p>0.05 (students t test).

this demonstrates that the synthetic A*56 oligomers are homogenous, relevant, stable, reproducible, and represent a single oligomeric species that potently impairs peptide and protein deg-
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radation by the 20S proteasome. These crosslinked A*56 oligomers are therefore ideally suited
for further mechanistic and biochemical analysis to understand how oligomers impair proteasome
function and are thus used in all of the following experiments using A oligomers unless stated
otherwise.
Direct binding of A*56 to 20S proteasome
We next sought to determine if A*56 and the 20S proteasome could be observed to directly
interact. Non-crosslinked A*56 oligomers were mixed with purified 20S proteasomes. To stabilize their interaction, we used a low concentration of glutaraldehyde (1mM) to induce crosslinking
and analyzed migration. A*56 is clearly seen co-migrating with the 20S proteasome by NativePAGE gel visualized with both silver stain (Fig. 3A left) and by immunoblotting for total A (Fig.
3A right). Notably, the low concentration of glutaraldehyde treatment did not cause random nonspecific protein crosslinking and did not crosslink the entire multisubunit proteasome into a single
700 kDa complex as determined by the absence of protein aggregates in the SDS-PAGE stacking
gel (Supplementary Fig. 7). Minimal crosslinking conditions are further demonstrated by the discrete banding pattern of multiple subunits and the persistence of two single subunit bands (Supplementary Fig. 7).
Toxic oligomers impair proteasome gate
Supplementary Figure 7. Corresponds to Figure 3A.
A*56 oligomers bind to the 20S
proteasome. (A) 20S proteasomes
(0.4g) and A*56 oligomers (1.5g)
(from Figure 3A) were incubated separately or together for 30 minutes
(37oC), were lightly crosslinked for
5min, and then separated by SDSPAGE (4-12% bis-tris gel). Total protein was detected by silver stain.
Lane 2 shows 20S proteasome migration pattern without crosslinking
for comparison. Lane 3 brackets denote intra-proteasome crosslinked
subunits after glutaraldehyde treatment (top bracket) and individual
subunits that did not crosslink (bottom bracket). The lack of aggregated
protein in the stacking gel (*) indicating minimal crosslinking conditions.

Substrates must pass through the gated translocation channel before gaining access to the
proteolytic sites44. The A11+ oligomers are too
large to enter the 13Å translocation channel
and directly inhibit -subunit active sites; however, they could be impairing 20S proteasome
function by impairing substrate entry through

88

the gate or by allosterically impairing the active sites. To address this question, we used the 3N
proteasome mutant, which has a constitutively open gate66. If the oligomers impair proteasome
activity by clogging the catalytic chamber or allosterically impairing the active sites, then they
should be able to impair the proteasome regardless if its substrate-gate is in the opened or closed
state. Alternatively, if the oligomers require a functioning gate for impairment, then they should
not be able to impair a proteasome with a constitutively open gate, i.e. the 3N 20S proteasome,
which lacks only 1 of its 7 -subunit N-termini44. We added the three different A11+ oligomers:
A*56, -Syn, and Htt-53Q, to the WT or the 3N 20S proteasome and monitored substrate
degradation. All three A11+ oligomers significantly impair wild-type proteasomes but do not impair
the 3N proteasomes (Fig. 3B-D). These results demonstrate that the A11+ oligomers require
a functioning gate in order to impair the 20S proteasome. In addition, most active site proteasome
inhibitors only inhibit one or two proteolytic sites, but the A11+ oligomers impair the degradation
of substrates specific for each of the three different catalytic sites (Fig. 3B-D), further supporting
a gating mechanism of impairment, since restricting substrate access would be expected to impair
all types of substrates. Moreover, a translocation channel clogging mechanism can also be ruled
out since the 3N 20S proteasome could not be impaired. To further confirm an allosteric mechanism of proteasome impairment, we performed a substrate saturation curve on the WT 20S
proteasome with and without A*56 oligomers. We used non-linear regression and the MichaelisMenten equation to analyze the KD and Vmax of the two curves. We found that the A*56 oligomers
caused a decrease in the Vmax (49.51 to 26.48 µM substrate) and an increase in the Km (9.816 to
18.57 µM substrate) (Supplementary Fig. 8), which is consistent with allosteric inhibition (i.e.
mixed inhibition—a form of noncompetitive inhibition). Taken together, these data clearly demonstrate that all three diseases-related oligomers impair proteasome function by a similar allosteric
mechanism, since all three A11+ oligomers require a closable gate on the 20S proteasome in
order to impair it.
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To validate the preparation of the open-gate 3N 20S proteasomes, they were incubated with
either a known gate-opening peptide (KANLQYYA45 from the C-terminus of Rpt5, which includes
the HbYX motif) or the -subunit active site inhibitor, MG132. Treatment with MG132 completely
inhibits WT and open-gate 3N proteasomes (Supplementary Fig. 9A) as expected for a pure
proteasome preparation. The Rpt5 peptide increases WT 20S proteasome substrate degradation
but failed to stimulate the open-gate 3N 20S proteasome (Supplementary Fig. 9B) as expected
for proteasomes with constitutively open gates. The preparations of pure 3N 20S were approximately 10 times more active than the WT 20S and thus ten times more WT 20S was used in
these experiments to obtain comparable basal rates (Supplementary Fig. 9).

Supplementary Figure 8. Corresponds to Figure 3.
Substrate saturation curve on the WT 20S proteasome with and without A*56 oligomers. Mammalian 20S proteasomes (0.5nM) were assayed for
nLPnLD-amc hydrolysis activity with and without
A*56 oligomers (1.2M) for 60 minutes at various
substrate concentrations. The rate of amc- hydrolysis
was plotted and line fit using non-linear regression
and the Michaelis-Menten equation (GraphPad version 7). Vmax and Km values are shown to the right.
Experiment was performed in triplicate.
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Supplemental Figure 9. Corresponds to Figure 3B-D.
WT and a3ΔN proteasome preparations have expected activities. (a) Chymotrypsin-like activity (LLVY-amc hydrolysis) is
abolished in both wild-type 20S and 3N 20S mutant proteasomes after pre-treatment with proteasome inhibitor MG132 (50M).
(b) Wild type 20S proteasomes (1.4 nM) show gate opening by addition of a known gate-opening peptide, Rpt 5 (300M). However, as expected the Rpt5 peptide could not stimulate the open-gate mutant 3N 20S proteasomes (0.14 nM). Note there is
10X more WT 20S than 3N 20S. Data is representative of three independent experiments performed in triplicate. Error bars
represent ± standard deviation. ****p<0.0001; ns p>0.05 (students t test).
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Toxic oligomers stabilize the proteasomes closed gate conformation
Binding of the 19S ATPases C-termini HbYX motif into the 20S intersubunit pockets induces a
conformational change of the 20S -subunits, which stabilizes the open state of the N-terminal
gating residues9,45. However, recent cryo-EM studies have highlighted the complexity of this gateopening mechanism in the 26S proteasome when the 19S binds to a substrate (or when it is
switched from an ATP-bound state to an ATPS bound state)67,68. It is less clear how the dynamics
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Figure 4. A11(+) oligomers cannot inhibit PA26 or PA28 induced gate opening. (a-c) 20S Proteasome activity with and
without the proteasome activator PA26 (1g/100l) was determined in the presence of A11(+) oligomers from A*56 (1.5M, A),
-Syn (0.1M, B), or Htt-53Q (0.1M, C). Broken graphs are used to show the extent of 20S inhibition while still showing the
extent of PA26 activation. (d) Proteasome activity in the presence of increasing concentrations of PA26 with and without A11(+)
A*56 (1.5M). The sigmoidal equation was fit to the averages from three independent experiments (normalized to % activity)
performed in triplicate, error bars ± S.E.M. For A, B, C, & D, the 20S proteasome activity (nLPnLD-amc hydrolysis, rfu/min) was
normalized to 20S control activity without activator. (e) Proteasome activity with PA26 activator (1g/100l) in the presence of
increasing concentrations of A*56 (left). Activity of 20S proteasome (without PA26) with 1.5M A*56 is shown at right. (f) Same
experiment as in A, with human PA28 replacing PA26. The concentrations of oligomers are calculated based on the respective
monomeric peptide/protein mass. All controls contained an equal volume of buffer identical to that of the respective aggregates.
Data is representative of three or more independent experiments performed in triplicate. Error bars represent ± standard deviation.
****p<0.0001; ***p<0.001; ns p>0.05 (students t test).
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of the gate changes when the 19S associates with the 20S. Nevertheless, functional studies have
shown that 19S binding to the 20S stimulates gate-opening in the 20S proteasome39,40, in a HbYX
motif dependent manner47. In contrast, the 11S family of proteasome activators (e.g. PA28
and PA26) bind to the 20S -subunits and facilitate gate opening by a different mechanism. Although the 11S subunits also bind to the -intersubunit pockets, they lack the HbYX motif and
thus do not induce -subunit conformational changes like the HbYX motif does. Instead, the 11S
internal “activation loop” is required for gate opening. This “activation loop” directly contacts the
base of the N-terminal gating residues and locally repositions them into the open conformation69.
We hypothesized that binding of the A11+ oligomers to the 20S may specifically impair one of
these distinct gate-opening mechanisms, which would provide evidence for the mechanism of
oligomer-mediated proteasome impairment. If the oligomers could impair the PA26-20S complex,
then it is expected that they would bind to the top of the 20S and compete with PA26 for binding
to the 20S. Alternatively, if the oligomers do not compete with PA26 for binding to the 20S but
they do impair the HbYX dependent gate-opening this indicates that oligomers must allosterically
affect conformational changes that are caused upon HbYX motif binding. Another possibility is
that the oligomers affect both or neither mechanisms of gate-opening. To assure that both ends
of the 20S proteasome were bound by PA26 we used saturating amounts to stimulate 20S peptide
degradation. None of the A11+ oligomers from A, -Syn, or Htt-53Q could impair the PA26-20SPA26 complex (Fig. 4A-C). Thus, the PA26-20S-PA26 complex mirrors the results obtained for
the 3N-20S. To evaluate this possibility that the oligomers compete with PA26 for binding to
the 20S we generated a binding saturation curve for PA26 to 20S by monitoring 20S proteasome
activation in the presence and absence of A11+ A*56 oligomers. The apparent affinity of PA26
binding for the 20S did not decrease in the presence of the A11+ oligomers (Fig. 4D), and the
oligomers did not impair PA26 at any concentration that was used, indicating that the oligomers
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do not compete with PA26 for binding to the 20S. Additionally, the A*56 oligomers could not
impair PA26 mediated gate opening even at very high A*56 concentrations (Fig. 4E).

**

***

**

ns

***

ns

Figure 5. A*56 oligomers inhibit ubiquitin-dependent and ubiquitin-independent degradation of full-length proteins. (ad) Purified human 26S proteasomes. (a) Human 26S proteasome activity (LLVY-amc hydrolysis, rfu/min) with 2M A*56 compared to buffer control. (b) Change in fluorescence of polyubiquitin-GFP fusion protein (Ub4(lin)-GFP-35) in the presence purified
human 26S proteasome, with and without 5M A*56. (c) Rate of polyubiquitin-GFP fusion protein (Ub4(lin)-GFP-35) degradation
in C (rfu/min). (d) Purified human 26S proteasomes were incubated with or without A*56 for 90 minutes at 37°C, and separated
by Native-PAGE and silver stained. Band density was quantified with ImageJ. Band density is shown as a percentage of total
density of each lane. (e-h) Full length protein degradation in mouse brain lysates. (e) Change in polarization of FITC labeledcasein in 2g mouse brain lysates, with and without 10M A*56. (f Rate of FITC-casein degradation in E (mP/min). (g) Change
in fluorescence of polyubiquitin-GFP fusion protein (Ub4(lin)-GFP-35) in 2g mouse brain lysates, with and without 10M A*56.
(h) Rate of polyubiquitin-GFP fusion protein (Ub4(lin)-GFP-35) degradation in G (rfu/min). The concentration of A*56 oligomers
is calculated based on Aβ monomeric peptide mass (4.5 kDa). All controls contained an equal volume of buffer identical to that of
the A*56 oligomers. Data is representative of three or more independent experiments performed in triplicate. Error bars represent
± standard deviation. ***p<0.001; **p<0.01; ns p>0.05. (students t test),
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The PA28 proteasome activator from humans is a homologue of PA26 and thought to open the
20S gate in a similar activation loop-dependent manner69. Consistent with PA26 results, the A11+
A*56 oligomers could not impair the human PA28 mediated proteasome gate opening (Fig.
4F). Therefore, the A11+ oligomers bind to the 20S proteasome at a location separate from the
11S proteasome activators, PA26 and PA28. Based on this we hypothesized that the oligomers
stabilize the latent closed conformation of the -subunits which is not affected by the PA26/28
activation loop-dependent gate opening. To test this hypothesis, we asked if the A11+ oligomers
could impair peptide and protein degradation by purified human 26S proteasomes. The A11+
A*56 oligomers significantly impaired peptide degradation by the purified 26S proteasome compared to controls (Fig. 5A).
To further test this possibility, we determined if oligomers could impair ubiquitin dependent
(Ub4(lin)-GFP-35) protein degradation by purified human 26S proteasomes. The Ub4(lin)-GFP-35
substrate we used to monitor ubiquitin dependent degradation is a circularly permuted GFP with
a linear tetra ubiquitin on N-terminus and a 35-residue unstructured region on the C-terminus that
was created in the Matousheck lab. We found that A*56 also strongly impaired the degradation
of this structured protein (Fig. 5B-C) by the human 26S proteasome, which requires ATP-dependent unfolding and injection into the 20S core. These data suggest the oligomers impair the HbYX
mechanism of gate opening. However, it is possible that the oligomer binding to the 20S could
cause the 26S to disassemble into its 20S and 19S subcomplexes, which could also have the
effect of impairing the ubiquitin-dependent protein degradation that we observed. To test this possibility, we incubated A*56 oligomers and purified human 26S proteasome preparations together
for 90 minutes at 37C before running the samples on native-PAGE (Fig. 5D). We quantified the
silver stain band densities for isolated 20S, singly capped 26S, and doubly capped 26S. The
relative ratio of these three populations of proteasomes did not change with the incubation with
A compared to control.
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The prior experiments where done with highly purified components thus providing good cause
and effect confidence for mechanistic analysis; however, the purified system cannot assess if the
oligomers are able to bind to and impair the proteasome in an environment that more closely
mimics a complex cellular environment. To address this, we prepared mouse brain lysates to
determine if the toxic oligomers could still impair protein degradation by the proteasome in such
a heterogeneous environment. We found that the brain lysates were highly competent to degrade
the protein substrates FITC-casein (Fig. 5E-F) and Ub4 (lin)-GFP-35 proteins (Fig. 5G-H) similar
to the purified 26S proteasome (Fig. 5B-C). We also assessed the proteasome activity component of this lysate by adding the proteasome inhibitor MG132, and found that the majority of the
degradation activity we observed was due to proteasome activity (Fig. 5E-H).
When we assessed the degradation of these two specific proteins in brain lysates, in the presence
of the crosslink-stabilized A*56 we observed extensive proteasome impairment—nearly as much
as when MG132 was used (Fig. 5E-H). Therefore, the A11+ A*56 oligomers retain enough
specificity to bind to and nearly completely impair proteasome function even in a complex brain
lysate. These data demonstrate that the oligomers do not disrupt the 26S complexes, and thus
do not impair it by this mechanism, but must instead act, as we expected, on the gate. Impairment
of the 26S proteasome also demonstrates that the oligomers must bind to the 20S even in the
presence of the 19S, as was also observed for the PA26-20S complexes, demonstrating that the
oligomers likely bind to the outer surface of the 20S proteasome (i.e. not on the gating surface)
thus supporting the hypothesis that these toxic oligomers act allosterically preventing the 20S
gate from opening properly. Since these results clearly demonstrate that A11+ oligomers are able
to impair the 20S core particle by itself, then it’s most likely that their impairment of the 26S proteasome is via the same mechanism, acting on the core particle. Importantly, this result demonstrates that A11+ oligomers can also impair proteasome function in a complex protein environment.
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The 19S requires binding of ATP for it to bind to and induce gate opening in the 20S 73. The 26S
proteasome adopts multiple conformations during the ATP hydrolysis cycle and substrate degradation67,74–76. In the presence of hydrolysable ATP, 26S proteasomes seems to alternate between
active (open gate) and inactive (closed gate) states, with the inactive state predominating, and in
contrast, non-hydrolyzing ATP analogues better stabilize the active (open gate) form of the proteasome67,77. Interestingly, while the A*56 oligomers impaired the 26S in the presence of ATP,
they could not impair the 26S in the presence of the analog ATPS (Fig. 6A). This shows that the
oligomers are able to impair the normal physiological (with ATP) state of the 26S but not the

Figure 6. HbYX-dependent 20S gate opening counteracts inhibition by A*56 oligomers.
(a) Mammalian 26S proteasome activity (LLVY-amc hydrolysis, rfu/min) with 2mM ATP or 10M ATPS. A*56 titration up to
6M. (b) 20S proteasome activity (nLPnLD-amc hydrolysis, rfu/min) with RPT5 peptide titration, with and without A*56 (0.5M).
(c) Schematic depicting our working model for proteasome inhibition by A11(+) oligomers (see text for details). The concentration of A*56 oligomers is calculated based on A monomeric peptide mass (4.5 kDa). All controls contained an equal volume
of buffer identical to that of the A*56 oligomers. Data is representative of three or more independent experiments performed in
triplicate. Error bars represent ± standard deviation.
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Supplemental Figure 10. Corresponds to Figure 6A.
The measured amc hydrolysis
from 26S proteasome preparation is due to single and double capped 26S activity and
not 20S activity. Native-PAGE
of 1g of mammalian rabbit muscle 26S proteasome. In-gel enzyme activity assay (LLVY-amc
hydrolysis) (left), silver stain
(right). Gel is representative of
three 26S proteasome preparations from rabbit muscle. Note
that the LLVY-amc activity is only
detectable from the 20S-19S
complexes in these experiments.

synthetically opened state (using ATPS), in
which the open state is more “strongly” stabilized. We verified the integrity of the purified
26S proteasomes preparation via NativePAGE to confirm that the observed activity
came only from the 26S complexes (Supple-

mentary Fig. 10) and not from any free 20S proteasome in the preparation. These results thus
further support the hypothesis that these oligomers oppose the HbYX-dependent conformational
changes that lead to gate-opening.
To further test this hypothesis, we asked if the A11+ oligomers could block HbYX-dependent gate
opening directly by the Rpt5 peptide (KANLQYYA), an established gate opening peptide45, derived from the C-terminus of Rpt5. We added increasing concentrations of the Rpt5 peptide to the
20S proteasome with and without the A11+ A*56 oligomers. In the absence of oligomers, the
Rpt5 peptide significantly stimulated proteasome activity as expected. However, the oligomers
impaired Rpt5 activation at all concentrations. Interestingly, the more Rpt5 was added the less
effective the oligomers were to impair the proteasome (Fig. 6B). These results indicate that the
oligomers impair HbYX dependent gate opening, but also that HbYX peptide could overcome
impairment by the oligomers at the higher concentrations (1mM Rpt5 peptide was the highest
concentration that could be tested due to its solubility). In contrast, the oligomers could not impair
PA26 activation at any concentration of PA26. We interpret these results to mimic the ATP/ATYS
experiment (Fig. 6A) whereby the ATP state is a low HbYX occupancy state and the ATPS state
is a higher occupancy HbYX state. The rational is that ATP is rapidly hydrolyzed to ADP, and ADP
cannot support HbYX-dependent gate-opening. On the other hand, ATPS is not hydrolyzed to
ADP and thus it sustains the HbYX bound open-gate state or it could also enhance gate-opening
by other mechanisms77. These combined results fit well with a model whereby the A11+ oligomers
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impair proteasome function by binding to the outer surface of the 20S barrel, and impair substrate
entry by allosterically stabilizing the closed conformational state of the 20S -subunits, in a way
that directly counteracts the conformational changes that are required for HbYX-dependent gateopening.
Discussion
The structural evolution of compartmentalized proteases was driven by the need to protect proteolytic activity from the cellular milieu, but still have the capacity to degrade select proteins in a
regulated manner. The substrate-entry gate in the 20S proteasome thus plays a critical role in
proteasome function and in cellular proteostasis. Here, we elucidate a common mechanism
whereby soluble oligomers possessing a common three-dimensional structure found in many
neurodegenerative diseases potently inhibit 20S and 26S proteasome gate-opening thus drastically impairing its function. While certain studies show some forms of aggregates do not impair
the proteasome (which we also find Fig. 1 B & D), the aggregates from these studies were not
assayed for the presence of A11+ oligomers. Based on our results we proposed the following
mechanistic model (Fig. 6C) of how A11+ oligomers impair proteasome function: 1) A11+ oligomers bind with low nM affinity (Fig. 1 & 2) to the outer surface of the -subunits along the C2 axis
(the presumed binding site); 2) by binding to this site the oligomers stabilize the closed conformation of the -subunits and prevent spontaneous gate-opening (Fig. 3); 3) activation loop-dependent gate opening (e.g. PA26) occurs normally in the presence of oligomers, since its mechanism only requires contact between the activation loops and the base of the gating residues (Fig.
4); 4) however, HbYX dependent gate-opening (e.g. the 19S regulatory particle or HbYX peptide)
is inhibited as oligomer-bound -subunits are unable to undergo the conformational changes required to open the gate (Fig. 5 & 6), which are stabilized by the bound oligomer. From a general
mechanistic perspective, in this model one expects to observe opposing allosteric controls fought
between two allosteric modulators that bind to distinct sites on the 20S proteasome. From this
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model, one expects to observe competition between two allosteric modulators (the HbYX motif
and the oligomers) that bind to distinct sites on the 20S proteasome. In this sense, the HbYX motif
is a positive allosteric modulator that induces gate opening, whereas the A11+ oligomers are
negative allosteric modulators that induce gate closing. These diametrically opposed regulators
thus fight to control the proteasome gate. Moreover, it appears that the HbYX mechanism is dominant since binding of the non-hydrolysable ATP analog, ATPS, prevents inhibition by A11+ oligomers (Fig. 6A), though further confirmation is warranted.
These results demonstrate that oligomer-mediated impairment of proteasome function is not dependent on the sequence of the misfolded protein but rather the oligomer’s three-dimensional
shape. Specifically, we found a consistent correlation between an oligomer’s ability to impair the
proteasome and recognition by the A11 antibody. While the physiological concentration of A11+
oligomers in neurons is unknown, if we consider that the affinity constant for the oligomers is low
nM, and that the cellular concentration of the 20S is estimated to be low micromolar 70 then, with
respect to this binding reaction, the 20S is saturating in the cell. This implies toxic oligomers will
bind to the 20S irrespective of their cellular concentration. Which begs the question: are physiological levels of A11+ oligomers sufficient to impact protein degradation? Using laser capture
microdissection and isolation of hippocampal pyramidal neurons from sporadic Alzheimer’s Disease cases, Hashimoto et al. (2010) determined the intraneuronal concentration of A42 to be
3M71, but what proportion of the intracellular A42 is in oligomeric form is not known. Furthermore, Kisselev et. al. (2006) showed that the amount of proteasome inhibitor, Velcade™ that is
used to treat multiply myeloma only inhibits protein degradation by about 10-25%72. This result
demonstrates that a relatively small alteration of protein breakdown can have a substantial impact
on cell death. Consistent with this reasoning, stereotaxic unilateral infusion of lactacystin (a selective proteasome inhibitor) into the substantia nigra pars compacta of rats caused neurodegenerative disease like symptoms22. However, the percentage of proteasomes that must be active in
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neurons to maintain normal proteostasis is not known and thus we could only speculate about
what level of intracellular A11 oligomers would be required to impact neuronal function. Nevertheless, as protein degradation begins to suffer as oligomers accumulate, the level of proteasome
impairment is expected to increase exponentially as more proteins accumulate and oligomerize.
Such a model would be expected to exhibit exponential progression kinetics, which coincides with
the exponential deterioration that is observed over decades in most neurodegenerative diseases.
These results build confidence that such oligomers in neurons could impair proteasome function
enough to contribute to the progression of these neurodegenerative diseases.
Future efforts are required to understand which structures within the A11 epitope facilitate 20S
proteasome binding and impairment and if this phenomenon occurs in human disease conditions.
Elucidation of this mechanism provides a compelling model to explain why proteasome function
has been found to be impaired in virtually all neurodegenerative diseases. Interestingly, Choi et.
al. (2016)78 showed that opening of the 20S proteasome gate in cells leads to enhanced cellular
proteasome function, including ubiquitin-dependent protein degradation, decreased protein aggregates, and protection from oxidative stress. Our model provides a mechanistic framework to
develop small molecules to counteract proteasome impairment via A11+ oligomers. Illustrating
this potential mechanism of proteasome impairment identifies novel drug targets for developing
small molecule activators of the proteasome gate. Such therapeutic interventions have the potential to restore proteostasis in patients suffering from neurodegenerative diseases.
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Materials and Methods
Proteasome purifications
Mammalian 20S proteasomes were isolated from bovine liver as described79. Briefly, cleared liver
homogenate was passed over DE53 column. Protein was eluted with a stepwise NaCl gradient.
Fractions with significant proteasome activity were pooled and further separated by a strong anion
exchange column (ResourceQ, GE Healthcare) eluting with NaCl gradient. Fractions with high
suc-LLVY-amc hydrolysis were pooled for further purification using a hydroxyapatite column
(CHT-I, Bio-Rad) and eluted by KPO4 gradient. Fractions with high proteasome activity were
pooled and further purified by SEC (S-400, GE Healthcare). Eluted fractions were pooled and
purity of 20S proteasomes (>98%) was determined by SDS-PAGE and quantified by densitometry
(ImageJ, NIH). Mammalian 26S proteasomes were isolated from rabbit muscle using the Ubl affinity purification as described80. Human 26S proteasomes were affinity purified on a streptavidin
column from the HEK293-4-biotin cell line as described78. Recombinant PA26 was expressed in
BL21-STAR E. coli and purified by affinity with a Ni-NTA column (Qiagen), as described81. Recombinant human PA28 was expressed in BL21-STAR E. coli and purified by affinity with a NiNTA column (Qiagen), as described82. Wild-type and mutant 3N yeast 20S proteasomes were
expressed and purified by anion-exchange chromatography as described83. Fluorogenic substrate peptides were purchased from BostonBiochem (suc-LLVY-amc) and EZBiolabs (acnLPnLD-amc and ac-RLR-amc). Rpt5 peptides were synthesized by EZBiolabs. Protein concentrations were determined by Bradford assay (BSA standard) (Thermo Scientific).
Proteasome activity assays – peptide substrates
Unless otherwise specified, bovine 20S (0.5 nM), rabbit muscle 26S (0.4 nM), yeast WT 20S (1.4
nM), or yeast 3N 20S (0.14 nM) proteasomes were assayed using fluorogenic peptides, as
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described45in 96-well black flat bottom untreated plates (Costar). Briefly, proteasomes were incubated in a reaction buffer containing 50mM Tris–HCl (pH 7.4), and 100M fluorogenic substrate
(suc-LLVY-amc, ac-nLPnLD-amc) or 10M fluorogenic substrate (boc-LRR-amc). 20S proteasomes were treated with Rpt5, or with PA28 or PA26 to induced gate opening as indicated.
Rabbit muscle 26S proteasomes were used in the presence of 1mM DTT, 10mM MgCl 2, and
100M of fluorogenic substrate (ac-nLPnLD-amc) with either 2mM ATP (99%, Sigma) or 10M
ATPS

(95%,

Sigma).

Fluorescence

was

measured

every

55

s

for

120

min

(ex/em:380nm/460nm). The rate of increase in fluorescence intensity is directly proportional to
proteasome activity. For all experiments, an equal volume of the appropriate control buffer (identical to the aggregate/oligomer buffer that is described below) was used for controls. All molar
concentrations of A, -Syn, and Htt-53Q are calculated based upon the monomeric protein concentration.
Proteasome activity assays – protein substrates
FITC-casein (0.08g, Sigma) and Ub4(lin)-GFP-35 (0.08g, a kind gift from Dr. Andreas Matousheck) degradation assays were carried out in 50l reactions using 96-half-well non-binding
surface treated black plates (Corning) at 37C. The GFP substrate was generated as described84.
Proteasomes were added to the reactions (1g 20S, or 0.9g human 26S) in the presence or
absence of A*56 oligomers (10M) and fluorescence was measured at every 60 seconds for 90
minutes. Data shown is the mean of three reactions, with a 5-point moving average, and error
bars represent +/- standard deviation. Degradation rates were determined by calculating the slope
of a line fit to the first 30 minutes of activity.
A 1-42 peptide
Synthetic A(1-42) was purchased from Selleckchem, Anaspec, and EZBiolabs. To remove
preexisting aggregates, synthetic A peptide was dissolved in 100% Hexafluoroisopropanol
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(HFIP), and incubated at 37C for 2 hours with shaking (500 RPM). The HFIP was removed and
the remaining peptide films were stored at -80C until use. Monomeric A was obtained by dissolving synthetic peptide in 100% anhydrous DMSO (Thermo Scientific) at 5mM and diluted with
PBS to a final concentration of 50M immediately prior to use. Crude A aggregates were prepared as described85. A*56 oligomers were generated similar to Barghorn et al. 200559. Briefly,
HFIP treated peptide films were resuspended in 100% anhydrous DMSO (5mM) and bath sonicated for twenty minutes before further dilution (400M) with 20mM NaPO4 pH 7.4, 140mM NaCl,
0.2% SDS. The 100M A was incubated at 37C for six hours, diluted to 100M with nanopore
H2O, incubated at 37C for 18 hours, centrifuged for 10 minutes at 3,000 g, and the supernatant
containing A*56 oligomers was removed and dialyzed against 5mM NaPO4 pH 7.4, 35mM NaCl.
Where indicated, A*56 oligomers were crosslinked (before dialysis) with 1mM glutaraldehyde
(EM grade, Thermo Scientific) for 2 hours at room temperature. The reaction was quenched by
the addition of 1M Tris-HCl pH 8 (to a final concentration of 10mM) and incubated for an additional
30 minutes. A*56 oligomers were purified by SEC (Superose 12 10/30, GE Healthcare) and
eluted as a single major peak. Each preparation of A*56 was confirmed to be A11+ by dot blot
analysis as described below. To generate A-HMW A11+ oligomers, the second A incubation at
100M was extended to 26 hours. To generate A A11+ protofibrils, the second A incubation at
100M was extended to 50 hours. The A A11+ protofibrils eluted from the Superose 6 column
in a single peak at the void volume and were confirmed to be >700 kDa by Native-PAGE. All
buffers were filtered with 0.2m membranes immediately prior to use. All SEC experiments were
performed on an ÄKTApurifier (GE Healthcare) at 4°C with 5mM NaPO4 pH 7.4, 35mM NaCl at a
flow rate of 0.5 mL/min. A concentration was calculated by UV absorption at 280nm (molar extinction coefficient 1940 M-1 cm-1) and confirmed with Bradford protein concentration assay
(Thermo Scientific).
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-Synuclein protein
Human wild-type -Synuclein (-Syn) with N-terminal his-tag in pET28a vector was expressed
and purified from BL21-STAR E. coli using a Ni-NTA column (Qiagen) followed by anion exchange
chromatography (HiTrapQ, GE Healthcare). Pure -Syn monomers were obtained by SEC (Superose 12 10/30, GE Healthcare) immediately prior to use. The purity of -Syn monomers (>98%)
was determined by SDS-PAGE and quantified by densitometry (ImageJ, NIH). Crude -Syn aggregates/oligomers were generated by incubating monomeric -Syn (3 mg/mL) in PBS (20mM
NaPO4 pH 7.4, 140mM NaCl) at 37C for 7 hours. After oligomerization, the oligomers were separated from the remaining monomers by SEC (Superose 12, GE Healthcare) and verified A11+
by dot blot.
Huntingtin protein
GST-tagged huntingtin exon1 constructs with a 53 polyglutamine repeat (GST-Htt-53Q) and a 20
polyglutamine repeat (GST-Htt-20Q). Protein was expressed and purified from BL21-STAR E.
coli as described86. Briefly, the GST-fusion protein was cleaved with PreScission Protease (GE
Healthcare) at 4C according to manufacturer protocol. The free Htt-53Q proteins were further
purified by SEC (Superose 12 10/30, GE Healthcare) to obtain a monomeric population immediately prior to oligomerization. The purity of Htt-53Q monomers (>95%) was analyzed with SDSPAGE quantified by densitometry (ImageJ, NIH). Oligomers were generated by incubating monomeric Htt-53Q (1mg/mL) at 37C for 1 hr. Due to the rapid formation of Htt-53Q oligomers, monomeric Htt-20Q (which oligomerized at a much slower rate) was used for the monomer assay in
Figure 1B.
Crude aggregate fractionation
Insoluble aggregates were removed from crude aggregate preparations by centrifugation at
10,000 x g for 10 minutes. The supernatant containing soluble oligomers was transferred to a
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fresh Eppendorf tube and the remaining pellet was gently resuspended in PBS. The pellet fraction
was centrifuged twice more before final resuspension at 1mg/mL in PBS. The fibrillar nature of
the insoluble fraction was confirmed by Thioflavin-T (Sigma) fluorescence in comparison to monomer preparation controls as described below.
SDS-PAGE and Native-PAGE
Proteins were separated by SDS-PAGE using NuPAGE™ 4-12% Bis-Tris Protein Gels (Invitrogen), or separated by Native-PAGE using Novex™ 10-20% Tris-Glycine or NuPAGE™ 3-8% TrisAcetate Protein Gels (Invitrogen), as indicated. Total protein was visualized with coomassie stain
(Simply Blue Safe Stain, Novex) or silver stain (Pierce Silver Stain kit, Thermo Scientific) as indicated according to manufacturer instructions. Immunoblots were performed as described below.
Native-PAGE in-gel 26S proteasome activity assay was performed using NuPAGE™ 3-8% TrisAcetate gels (Invitrogen). Samples were mixed with Novex™ Tris-Glycine Native Sample Buffer
(2X) (Invitrogen) just before loading. Electrophoresis was carried out in Novex™ Tris-Glycine Native Running Buffer (Invitrogen) (with 0.5mM DTT, 1mM ATP, and 5mM MgCl2) at 4°C and 150V
for 4 hours. Native gels containing 26S proteasomes were incubated with reaction buffer (50mM
Tris pH 7.5, 10mM MgCl2, 2mM ATP, 1mM DTT, 50M suc-LLVY-AMC) for 30 min at 37°C. Fluorescent bands around proteasomes were visualized by standard gel-imaging systems for DNA
staining by ethidium bromide.
Immunoblotting
For Native-PAGE Western blots, proteins were transferred to nitrocellulose membrane (GE) using
tris-glycine transfer buffer (Novex). Primary antibodies were purchased from Invitrogen (anti-oligomer A11, and anti-A N-terminus clone NAB228) and diluted 1:1000 in TBST (50mM tris, 150
mM NaCl, 0.01% Tween-20) + 5% nonfat milk prior to use. AlexaFluor-647 conjugated secondary
antibodies (Invitrogen) were diluted 1:3500 in TBST prior to use. Membranes were blocked for 1
hour at room temperature in TBST + 10% nonfat milk, briefly washed with TBST, incubated with

106

primary antibody for 1 hour at room temperature, washed with TBST (3 x 5 minutes), incubated
with secondary antibody for 1 hour at room temperature, washed (3 x 5 minutes), and imaged on
a Molecular Dynamics Typhoon 9410 Variable Mode Imager. Dot blots were performed by spotting protein on 0.1M nitrocellulose membranes and processed the same as Western blots.
Antibody neutralization assays
Anti-oligomer A11 (Invitrogen) and A N-terminal antibody (clone NAB228, Invitrogen) were buffer
exchanged to 50mM Tris (pH 7.4) with Zeba spin desalting columns (Thermo Scientific). The
antibodies (0.5g) were incubated with A*56 (50M) or control buffer for 25 minutes at 37C
before adding to proteasome activity assays.
Crosslinking A*56 and 20S proteasomes
Mammalian 20S proteasomes were buffer exchanged to 10mM NaPO4 (pH 7 with Zeba spin desalting columns (Thermo Scientific) and incubated with A*56 oligomers (or an equal volume of
control buffer) for 45 minutes at 37C. 1mM Glutaraldehyde was added to the mixture of 20S
proteasomes and Aβ*56 oligomers and incubated for 5 minutes at 37C. Crosslinking reactions
were quenched by the addition of 1M Tris-HCl pH 8 (1mM). Proteins were separated by SDSPAGE and Native-PAGE and visualized with silver stain or immunoblotting as described above.
Oligomer characterization
For atomic force microcopy imaging, preformed A oligomers were deposited on freshly cleaved
mica (Ted Pella Inc., Redding, CA) and allowed to sit for 30 s. The mica substrate was then
washed with 200L of ultrapure water and dried with a gentle stream of nitrogen. Samples were
imaged in tapping mode via ex situ AFM using a Nanoscope V MultiMode scanning probe microscope (Veeco, Santa Barbara, CA). AFM images were analyzed with Matlab equipped with the
image processing toolbox (Mathworks, Natick, MA). For negative stain electron microscopy, 6l
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of preformed A*56 oligomers were applied to ultra-thin copper 400 mesh carbon grids (Electron
Microscopy Sciences) and imaged on a JEOL JEM-2100 Transmission Electron Microscope.
Thioflavin-T florescence measurement
Thioflavin-T (ThT) (Sigma) was dissolved (1mM) in PBS, filtered through a 0.2M syringe filter,
and stored at -20°C until use. For the assays, 3g of A was incubated at room temperature for
10 minutes in 100M of PBS with 20M ThT and fluorescence was measured (ex/em:
450nm/490nm) in a Synergy2 plate reader (GenTek).
Statistical analysis
Data were analyzed using an unpaired Student’s t-test (Prism). For all statistical analyses, a value
of p < 0.05 was considered significant.
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Abstract
Proteostasis is maintained by several systems in the cell including the ubiquitin-proteasome system (UPS), chaperones, chaperone-mediated autophagy, and macroautophagy. The UPS is the
principle route for the degradation of intracellular misfolded, damaged, or unneeded proteins. At
the center of the UPS is the proteasome, a large and complex molecular machine containing a
multicatalytic protease complex. When the efficiency of this proteostasis systems is perturbed,
misfolded and damaged protein aggregates can accumulate to toxic levels and cause neuronal
dysfunction, which may underlie many neurodegenerative diseases. The 20S proteasome substrate-entry gate plays a critical role in proteasome function and in cellular proteostasis and the
molecular mechanisms of gating remain poorly understood. In this study we develop a novel
compound that promotes proteasome gate opening to increase the degradation rate of peptides
and proteins. These results provide a new tool for investigating proteasome function and provide
proof -of-concept development of gate-activating compounds.
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Introduction
The ubiquitin-proteasome system (UPS) is responsible for more regulated protein degradation in
eukaryotes and regulates myriad cellular processes, such as the cell cycle, apoptosis, the immune
response, inflammation, and the response to proteotoxic stress1,2. Proteins selected for degradation are typically modified by the covalent attachment of ubiquitin chains, which targets it to the
26S proteasomes for degradation2,3. The 26S proteasome is a complex and highly regulated 2.5
MDa peptidase complex, comprised of a barrel-shaped proteolytic 20S core particle with a 19S
ATPase regulatory particle capped on one or both barrel ends 4. Ubiquitinated proteins are degraded in a multistep process; the 19S regulatory particle binds ubiquitinated substrates, opens
a substrate entry gate in the 20S5,6, and unfolds its substrates by linearly translocating them into
the 20S catalytic chamber where they are degraded to peptides4,7.
Compartmentalized proteases protect the cellular milieu from proteolytic activity and retain the
capacity to degrade specific proteins in a regulated manner. Eukaryotic 20S proteasomes have
four stacked heteroheptameric rings arranged in an α1-7-β1-7-β1-7-α1-7 fashion8. The two β rings
form a catalytic chamber with three different peptidase activities (chymotrypsin-like site (β5) preferentially cleaves after hydrophobic residues, the trypsin-like site (β2) preferentially cleaves after
basic residues, and the caspase-like site (β1) preferentially cleaves after acidic residues4,9). The
α subunits’ amino(N)-termini extend over the 13 Angstrom central pore and form a gate, which
occludes access to the proteolytic sites located inside10,11. The 20S proteasome substrate-entry
gate plays a critical role in proteasome function and in cellular proteostasis. The α3 N-terminus is
the lynchpin and forms salt bridges with neighboring N-termini to stabilize the closed gate confirmation12. Deletion of the first eight α3 residues α3∆N (α3∆N-20S) sufficiently destabilizes the
closed-gate conformation and accelerates the entry and degradation of peptides12. Wild type 20S
proteasome activity is similarly accelerated when bound to a proteasome activator (e.g.
19S/PA700, 11S/PA28, Blm10/PA200)13.
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Proteasome activators bind to one or both ends of the 20S core particle by inserting one or more
C-termini into pockets between adjacent 20S α subunits (intersubunit pockets). Proteasome activators stabilize the conserved proline reverse turn (at the base of the N-termini gate) in the “open”
conformation, using two different mechanisms. Most proteasome activators’ C-termini
(19S/PA700, Blm10/PA200, PAN) contain a hydrophobic-tyrosine-X (HbYX) motif (Figure 1A,B).
The penultimate tyrosine forms a hydrogen bond with the proline reverse turn to stabilize the open
conformation and trigger gate opening14,15. In contrast, the C-termini of 11S/PA28/PA26 family of
proteasome activators do not have a HbYX motif, instead they use an internal activation loop to
contact and reposition the proline reverse turn16.
Recent structural studies (cryo-EM) of the eukaryotic 26S proteasome highlight the complexities
of 26S gate opening. Several studies suggest that the conserved HbYX motif of three 19S subunits (Rpt2,Rpt3,Rpt5) stably insert into the intersubunit pockets without causing full gate opening17–20. In contrast, functional studies have shown that 19S binding to the 20S stimulates gateopening in the 20S proteasome6,21, in a HbYX motif dependent manner22, and binding of the HbYX
motif by itself (as a hepta-peptide) is also sufficient to allosterically induce conformational changes
in the α-subunits that cause gate opening14,15. Hence, the molecular mechanism of gating by the
RP and how the gate dynamics change when a the 20S associates with an activator remains
poorly understood. Drugs or genetic mutations that increase proteasome activity restore proteostasis in cellular models of neurodegenerative disease23–25. Therefore, there is a need for a better
understanding of the 20S gate mechanism.
In this study we design a small proteasome activator (ZYA) based on the molecular interactions
of the conserved C-terminal HbYX motif in proteasome activators. We show that ZYA activates
proteasome function by opening the 20S gate to increase degradation of both peptide and protein
substrates. ZYA has potential application as a research tool to study proteasome function in vitro
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and in vivo, and we demonstrate the feasibility of designing drug-like molecules to activate proteasome function to treat patients with neurodegenerative diseases.
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Figure 1. Proteasome activators - HbYX motif docking into 20S α ring. A. Surface representation of 20S proteasomes in
complex with activators [Human 26S (PDB 6msk), yeast 20S+Blm10 (PDB 4v7o), archaeal 20S + PAN (PDB 6hed)]. HbYX motifs
visible are colored vermillion and adjacent α-subunits of the visible HbYX motif are shown in color. B. Surface representation of
20S a rings from (A). Proteasome activator C-termini with HbYX motif bound to α-intersubunit pockets are vermillion (surface). C.
Overlay of 20S intersubunit pockets (cartoon) from (B) with HbYX motif residues (sticks). Crystal structure of PAN C-terminus
(PDB 3ipm) is shown in place of cryo-EM PDB 6hed. Images were rendered with PyMOL.
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Results and Discussion
The conserved HbYX motif is found in proteasome activators from archaea to humans. We
aligned activator-bound intersubunit α pockets from human (PDB 6msk17, cryo-EM), yeast (PDB
4v7o26), and archaeal proteasomes (PDB 6hed27, cryo-EM) (Figure 1C). As expected, the C-terminal HbYX motif bound to the intersubunit pockets in similar orientations, with the C-terminal
carboxylic acid directed towards the conserved pocket lysine (which is required for 20S proteasome-activator complex formation14) and the penultimate tyrosine hydroxyl group oriented toward the proline reverse turn (located at the gate base). These two interactions are critical for
HbYX motif binding to and activating the proteasome gate14,15,28. Our aim was to further characterize the HbYX binding pocket and apply this information to the design of small synthetic gate
activating molecules.
The intersubunit pockets contain many conserved residues, some of which are known to be important for gate activation (e.g. Pro17, Lys66)28,29. We investigated the effect of mutations to three
conserved residues positioned near the bound HbYX motif (Figure 2A). For mutational analysis,
we used the archaeal (Thermoplasma acidophilum) 20S because it is a homoheptamer, amenable to mutational studies, and easily expressed in E.coli. Consistent with previously published
results14, Lys66Ala mutation prevented PAN30 (the archaeal homologue of the 19S) activation of
the 20S (Figure 2B). Lys33 is located at the base of the α-helix leading toward the proline reverse
turn. When K33 is mutated to a glycine, 20S activity was less than half that of the wild type and
was not stimulated by PAN. This could be due to a disruption of the helices by inserting the secondary structure-destabilizing glycine, or by loss of the K33 ε-amine bonding interactions. Leucine
81 forms the bottom of the HbYX pocket directly underneath the HbYX tyrosine. Loss of this
hydrophobic residue (by mutation to alanine or glycine) prevents PAN mediated proteasome activation (Figure 2B), suggesting this residue is important for stabilizing HbYX motif binding. We
noted the proximity of Leu81 to the reverse turn backbone (Gly19). Considering the importance
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of HbYX tyrosine hydrogen bonding with the backbone, we asked if a tyrosine substitution at this
position would mimic the effect of a bound HbYX motif. Surprisingly, proteasomes with the
Leu81Tyr mutation (αL81YT20S) had over three-fold greater basal activity compared to wild type
(Figure 2C), suggesting this mutation stabilizes the open-gate conformation. In agreement with
this, addition of PAN to αL81YT20S proteasomes only resulted in 30% increased activation,
whereas an equal amount of PAN increased wild-type T20S activity greater than five-fold (Figure
2C). These data show that 20S gate activation can be achieved by small scale alteration of the
intersubunit pocket.

Figure 2. Highly conserved
α-intersubunit
pocket residues are required for PAN-HbYX
gate activation. A. Multiple sequences alignment
(20S α6 protein) generated
with
CLUSTAL
OMEGA (1.2.4). B. Left,
conserved residues interacting with the bound
HbYX motif (sticks) are
shown in the t20S intersubunit binding pocket
(PDB 3ipm). The PAN
HbYX motif (LYR) is
shown in cyan (stick).
Right, t20S proteasome
(0.2 µg of wild-type or
K66/K33/L81
mutants)
and fluorogenic octapeptide (LFP) are incubated
with or without PAN and
ATPγS. The stimulation of
gate opening was measured by the increase of
LFP hydrolysis (rfu/min)
over wild-type 20S without
any activator. C. Left,
same as (B), with L81 mutated to tyrosine (magenta
stick). Right, experiments
with t20S proteasome (0.2
µg of wild-type or L81Y
mutant) performed same
as in (B). Images in (B)
and (C) were rendered
with PyMOL. The data are
representative of three or
more independent experiments performed in triplicate. Error bars represent ± standard deviation.
Panels
B and
C:
***p<0.0001; ns p>0.05.
(students t test), P-value
compared to t20S basal
activity.
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Previous studies showed that short (3-6 amino acid) peptides with a C-terminal HbYX motif (corresponding to the PAN C-terminus) did not activate the 20S gate14,15. This contrasts with our
Leu81Tyr mutation data, from which we hypothesized small HbYX motif peptides can activate the
gate. The 3-8 amino acid peptides used in Smith et al. (2007)14 were synthesized with unmodified
N-termini, and this positive charge may prevent shorter HbYX peptides from binding in the intersubunit pocket. To test this hypothesis, we synthesized N-terminal acetylated peptides corresponding to the PAN C-terminus from three to eight residues in length (CT3-8). In contrast to
previous results14, PAN CT peptides shorter than seven residues stabilized the open 20S gate
(Figure 3A). Based on the successful gate-activation of PAN CT3 (Ac-LYR), we designed a small,
novel dipeptide to mimic the HbYX-motif. We substituted an alanine in place of the bulky arginine
residue to decrease the dipeptide size, as this substitution did not alter ability of PAN-CT8 peptide
to bind α intersubunit pockets and open the gate14,15 in previous studies. Capping the tyrosine N-

Figure 3. HbYX of peptides of different lengths
to stimulate gate opening.
A. Peptides (200 µM) were
incubated with 0.2 µg t20S
proteasomes and 10 µM
LFP substrate. A correction
was made because the
added peptides also compete with LFP at the active
sites. To determine the actual percentage stimulation
of LFP hydrolysis due to
gate opening, the ability of
the various peptides to inhibit LFP hydrolysis by the
gateless (2–12) 20S proteasome was also measured, and the values were
used to normalize data on
LFP hydrolysis by wild-type
20S proteasomes. Without
normalization, the three- to
five-residue peptides still
stimulated
20S
proteasomes 2- to 3-fold. B.
0.2 µg t20S proteasomes
incubated with 10 µM LFP
substrate and DMSO or 200
µM ZYA. LFP degradation
rate (rfu/min) is normalized
to DMSO. The data are representative of three or more
independent experiments
performed in triplicate. Error
bars represent ± standard
deviation.
***p<0.0001;
**p<0.01 (student t test), Pvalue compared to DMSO.

(200 µM )
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terminus with a carboxybenzyl group allowed the synthesis of a dipeptide that retained a hydrophobic group preceding the tyrosine. We tested ZYA with T20S proteasomes and observed almost 6-fold activation (Figure 3B).
Our next step was to test ZYA with the more complex heteroheptameric 20S proteasomes found
in eukaryotes. Consistent with our previous results, ZYA activated the mammalian 20S proteasome (Figure 4A). When the charged carboxylic acid was modified with NOH2 group, (i.e. no
longer carried a negative charge) ZYA-[NOH2]
failed to activate the proteasome (Figure 4A).
Since the charged C-terminus is critical for HbYX
mediate gate activation, we evaluated the effect
of adding additional negative charges to the
HbYX-motif dipeptide (ZYD, ZYE), a backbone
torsion constraint (ZYP), and a polar group
(ZYQ). None of these “X” modifications activated
the mammalian 20S proteasome (Figure 4A).
Since hydrogen bonding between the HbYX hydroxyl group and G19 in the proline reverse turn
is important for gate activation by proteasome
activators and their C-terminal peptides31, we determined the effect of modifying the ZYA tyrosine. The tripeptide Ac-YFA partially activated
the 20S proteasome gate (Figure 4B). Although

Figure 4. Effect of ZYA derivatives on proteasome gate
activation. A. Mammalian 20S proteasome activity
(nLPnLD-amc hydrolysis, rfu/min) with the indicated ZYA
derivatives at 250 M. Proteasome activity is normalized to
DMSO. B. Mammalian 20S proteasome activity (nLPnLDamc hydrolysis, rfu/min) with the indicated ZYA derivatives
at 100 M. Ac, acetylated; nitro-Tyr, nitrotyrosine; pY,
phosphotyrosine, 4-amino-Phe, 4-Amino-L-phenylalanine.
Proteasome activity is normalized to DMSO. The data are
representative of three or more independent experiments
performed in triplicate. Error bars represent ± standard deviation. ****p<0.0001; ***p<0.001; **p<0.01; *p<0.05; ns
p>0.05 (student t test, P-value compared to DMSO).
‡p<0.05 (student t test, P-value compared between two
groups as indicated by brackets).
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L81

LLVY-amc nLPnLDamc

RLR-amc

Figure 5. ZYA activates the proteasome
gate. A. ZYA (green sticks) docked into the
human 5/6 intersubunit pocket. Conserved
G19 and K62 (corresponding to K66 in T. acidophilum 20S) shown as cyan sticks. Yellow
arrow points to L81. Image was rendered in
PyMOL. B. Mammalian 20S proteasomes
(0.5 nM) were incubated with 1 mM ZYA and
100 µM of the indicated peptide substrate.
Proteasome activity (linear rate of substrateamc hydrolysis) is normalized to DMSO controls. C. Yeast wild-type and gate mutant
α3∆N 20S proteasomes incubated with 500
µM ZYA. Proteasome activity (linear rate of
nLPnLD-amc hydrolysis) is normalized to
DMSO controls. D. Mammalian 20S proteasomes (0.5 nM) were incubated with ZYA
at the indicated concentrations. Proteasome
activity (linear rate of substrate-amc hydrolysis) is normalized to DMSO control. The data
are representative of three or more independent experiments performed in triplicate.
Error bars represent ± standard deviation.
Panels B and C: ****p<0.0001; ***p<0.001;
ns p>0.05. (student t test).

not a strict C-terminal HbYX motif, this peptide retains a tyrosine, and it is worth noting that some
eukaryotic proteasome activators have a -YYA HbYX motif (i.e. human Rpt5, yeast Blm10). The
ability of Ac-YFA to activate the proteasome gate suggests the intersubunit binding pocket is
“flexible” as to what peptides it can successfully bind. Modifications disrupting hydrogen bond
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donating availability of the ZYA tyrosine hydroxyl group (Z-pY-A and Z-[3,nitroTyr]-A) do not activate the proteasome (Figure 4B). Interestingly, when 4-aminophenylalanine is substituted for the
tyrosine (Z-[4,aminoPhe]-A) the proteasome is activated like ZYA (Figure 4B). Unlike phosphotyrosine and 3-nitrotyrosine, 4-aminophenylalanine’s mass and polar surface area is like tyrosine’s,
and it has the same hydrogen bond availability. These results are consistent with the computational docking model of ZYA in the human α 5/6 intersubunit pocket (Figure 5A).
Our next aim was to use biochemical methods to confirm ZYA activates the 20S proteasome by
stabilizing the open gate conformation. Eukaryotic proteasomes have three different types of active sites, and stabilization of the open gate conformation increases activity from all three sites.
We tested the effect of ZYA on proteasome hydrolysis of three substrates preferentially cleaved
by different sites (LLVY-amc, β5; nLPnLD-amc, β1; LRR-amc, β2). As expected, ZYA increased
the hydrolysis rate of all three substrate peptides (Figure 5B). To confirm ZYA indeed influences
the 20S gate, we performed activity assays using yeast 20S proteasomes with a gate mutation
(α3∆N) that prevents the gate from fully closing10. The α3∆N proteasome gates allow substrate
peptides unrestricted access to the proteolytic core. While ZYA activates wild-type yeast proteasome activity, it does not increase α3∆N proteasome activity (Figure 5C). We titrated ZYA with
20S proteasomes to determine maximum activation and affinity. Although ZYA can stimulate proteasome activity over 40-fold, it has poor affinity (Figure 5D). Interestingly, ZYA has hill coefficient
of 1.5 indicative of positive cooperative binding, which matches recently proposed cryo-EM structural models for 19S RPT C-termini opening the gate17–20.
While we have demonstrated ZYA activates peptide hydrolysis via opening its gate, changes in
peptidase activity do not necessarily reflect changes in the proteasome’s capacity to degrade
proteins. To evaluate the efficacy of ZYA to stimulate protein degradation, we used SDS-PAGE
to measure the effect of ZYA has on proteasome degradation of tau23 (a truncated tau protein)
and casein, which are protein substrates of the 20S. ZYA significantly increased the degradation
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D.

C.

Figure 6. ZYA activates protein degradation and prevent proteasome impairment by neurodegenerative-disease associated oligomers. A. Mammalian 20S proteasomes incubated with tau23 (truncated tau protein) or β-casein. At the indicated times,
the reaction was quenched by addition of SDS loading buffer and separated by SDS-PAGE. Proteins visualized with Coomassie
brilliant blue. Gels are representative of three independent experiments. 20S proteasome subunits are indicated with brackets to
serve as loading controls for each sample. B. Mammalian 20S proteasomes (2 µg) incubated with fluorescamine labeled β-casein
(2 µg) and DMSO or 2 mM ZYA for 35 min. The acid-soluble degradation products were measured by using the fluorescamine
reaction. Values are means ± SD of three experiments. C. Mammalian 20S proteasome (0.5 nM) activity (nLPnLD-amc hydrolysis,
rfu/min) with ZYA at the indicated concentrations, with and without A*56 (0.5 M) oligomers (Thibaudeau et al., 2018). D. Mammalian 20S proteasomes (0.5 nM) incubated with and without -Syn [top] or Htt-Q53 [bottom] oligomers (Thibaudeau et al., 2018)
and DMSO or ZYA (1 mM). Rate of nLPnLD-amc hydrolysis is normalized to the control. The data are representative of three or
more independent experiments performed in triplicate. Error bars represent ± standard deviation. ***p<0.001; **p<0.01; *p<0.05;
ns p>0.05. (student t test).

of both proteins (Figure 6A). In support of these results, we measured 20S proteasome degradation of β-casein (Figure 6B). In agreement with the gel-based protein degradation assay, ZYA
significantly increased proteasome degradation β-casein.
Thus far we have demonstrated ZYA increases peptide and protein degradation by increasing
20S proteasome gate-opening. We recently published a study demonstrating protein oligomers
associated with neurodegenerative diseases (Aβ, α-synuclein, and huntingtin with a Q53 expansion) impair proteasome function by stabilizing the closed gate conformation 2019. This study
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showed an 8-amino acid HbYX peptide derived from the Rpt5 C-terminus partially restored proteasome activity in the presence of these oligomers. Remarkably, when proteasome activity is
measured in the presence of oligomers, the addition of ZYA completely restores proteasome
function (Figure 6C). This is an important demonstration for the potential small molecules to restore activity in conditions of proteasome impairment.
Concluding Remarks
The proteasome is a highly regulated multi-subunit complex and possesses multiple drug targets
to modulate its degradation capacity. The first compounds to target the proteasome inhibited the
proteolytic sites in the 20S core particle. In fact, early understanding of the importance of the
proteasome for biological functions and processes rapidly advanced with the introduction of the
first proteasome inhibitors32. More recently, compounds targeting a 19S-associated deubiquitinase (USP14) have been developed. Treatment of cultured cells with these inhibitors can increase the rate of degradation of a subset of proteasome substrates33, and accelerate the rate of
degradation of wild-type and pathological tau mutants34. In contrast, development of compounds
to stimulate gate-opening have received little attention. Recent structural studies (cryoEM) of the
eukaryotic 26S proteasome highlight the complexities of 26S gate opening. Considering the importance of the proteasome gate in regulating protein degradation, gate-activating compounds
(such as ZYA) have great potential as research tools to probe proteasome function in vitro and in
vivo.
Decreased proteasome function has been reported in a broad array of chronic neurodegenerative
diseases35, and proteasomal upregulation accelerates the clearance of pathogenic proteins. Studies suggest the elevation of proteasomal activity is tolerable to cells and may be beneficial to
prevent the accumulation of protein aggregates. For example, Cells treated with exogenous pro-
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teasomes are more efficient in degrading overexpressed human tau than endogenous proteasomal substrates, resulting in decreased levels of tau aggregates 36. Similar results are seen
in cells expressing the α3∆N open gate mutant proteasome37. Our study offers proof of concept
for the design of small molecules that open the proteasome gate.
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Materials and Methods
Proteins and peptides
T.acidophilum wild type 20S and Δα2-12 20S proteasomes were purified as described30. All 20S
mutants were generated by overlapping PCR site-directed mutagenesis. The plasmid for M.jannaschii PAN(M74A), kindly provided by Dr. Peter Zwickl30, lacked a His Tag and was purified as
described38, but Tris buffers were made at 50 mM instead of 20mM. Mammalian 20S proteasomes were isolated from bovine liver as described39. Wild type and mutant α3ΔN yeast
20S proteasomes were expressed and purified by anion-exchange chromatography as described40. Fluorogenic substrate peptides were purchased from BostonBiochem (suc-LLVYamc) and EZBiolabs (ac-nLPnLD-amc, ac-RLR-amc, LFP (Mca-AKVYPYPME-Dpa(Dnp)-amide)), PAN CT peptides, ZYA, and ZYA derivatives were purchased from Abclonal. Oligomers
of Aβ*56, α-synuclein, and huntingtin-Q53 were prepared as described 41. All oligomers used
were recognized by the α-oligomer antibody, A11 42. Protein concentrations were determined
by Bradford assay (Thermo Scientific).
Enzyme assays
To measure peptide hydrolysis, fluorogenic peptides in DMSO were used at a final concentration
of 100 μM for Suc-LLVY-amc and Ac-nLPnLD-amc, and 10 μM for LFP and Boc-RLR-amc, in 50
mM Tris (pH 7.5), 1 mM DTT. For archaeal 20S, LFP peptides were added to the buffer at
45°C, and where indicated, 1 μg of PAN and 10 µM ATPγS (+5 mM MgCl2) was added to the 0.1
ml of reaction buffer (sufficient to saturate the 20S particles)43. Assays with mammalian (0.5 nM
and 1 nM as indicated), yeast wild-type (2 nM), and yeast α3∆N (0.2 nM) proteasomes were
performed at 37°C. Assays with Aβ, α-synuclein, and huntingtin-Q53 oligomers were performed
as described41.
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Degradation of proteins
Tau23 or β-casein were incubated with mammalian 20S proteasomes for the indicated time at
37oC. Reactions were quenched by addition of LDS sample buffer (Invitrogen). Proteins were
separated by SDS-PAGE using NuPAGE™ 4–12% Bis-Tris protein gels (Invitrogen) and visualized with coomassie brilliant blue. The degradation products from β-casein were measured by
using the fluorescamine reaction, as described previously43.
Statistical analysis
Data were analyzed using an unpaired Student’s t-test (Prism). For all statistical analyses, a value
of p < 0.05 was considered significant.
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General Discussion
The structural evolution of regulated proteases was driven by the need to protect proteolytic activity from the cellular milieu, but still have the capacity to degrade select proteins in a regulated
manner. The substrate-entry gate in the 20S proteasome thus plays a critical role in proteasome
function and in cellular proteostasis. Maintaining proteostasis is especially important for neurons
due to their complex architecture, long lifespan, and inability to dilute aggregate load by cell division1. Moreover, proteasomal degradation is critical for normal functioning of neuronal synapses,
including synaptic protein turnover, plasticity, and long-term memory formation, which rely on
tightly controlled changes in the proteome1–4. As dysfunction in proteasomal degradation has
been implicated in many human diseases, biochemical and structural analysis of the proteasome
is essential to advance our understanding of its action and regulation mechanisms.
I. Mechanism of proteasome impairment by protein oligomers
It is well established that proteasome function is decreased in neurodegenerative diseases, and
impaired function has been implicated in the development of many neurodegenerative diseases,
including Alzheimer’s, Parkinson’s, and Huntington’s disease5–9. Study 1 identified a common
mechanism of proteasome impairment by neurodegenerative disease associated protein oligomers. We showed that oligomers from three different ND associated proteins adopt a similar 3D
conformation and stabilize the proteasome
gate in the closed conformation, thereby restricting substrate entry into the catalytic 20S
proteasome core. Taken together, biochemical
data from Study 1 suggests oligomers stabilize
the closed gate by binding to the -intersubunit
cleft on the side of the proteasome (Figure 1).

Figure 1. Proposed mechanism of oligomer-mediated proteasome impairment. Oligomers with the A11 conformation
bind to the intersubunit pocket and stabilize the closed gate.
HbYX, hydrophobic-tyrosine-any residue motif. See Study 1
for details.
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I.A. Targeting oligomer-proteasome interactions
Protein-protein interactions (PPIs) represent a vast class of therapeutic targets both inside and
outside the cell. Twenty years ago, PPIs were deemed intractable drug targets10. Thanks to recent
advances in our understanding of PPIs, more than 40 PPIs have been targeted and several PPIinhibitors have reached clinical trials11–13. Increased proteasome activity has been shown to have
a protective cellular effect and extend lifespan14–17, therefore preventing oligomer-proteasome interactions has the potential to restore proteasome function in neurodegenerative disease. Understanding the structural interactions of oligomers with the proteasome is the foundation for designing protein-protein interaction (PPI) inhibitors that prevent oligomers from binding to the proteasome.
Mass spectrometry combined with hydrogen/deuterium (H/D) exchange is used to study the conformation and dynamics of proteins. H/D exchange can be used in a comparative manner to identify changes in protein conformation and dynamics induced by ligand binding or protein-protein
interactions18,19. Analysis of oligomer-proteasome interactions with H/D exchange techniques can
provide identification of the oligomer binding site, and further elucidate changes in proteasome
gate dynamics due to oligomer-proteasome interactions.
Chemical crosslinking is another important tool for mapping protein three-dimensional structures
and protein-protein interactions20. In recent years, new crosslinking/mass spectrometry (XL-MS)
approaches have been developed to study proteasome structural conformations and proteasomeinteracting proteins21–23. For example, using two cross-linkers, bis (sulfosuccinimidyl) suberate
and its water-insoluble analog disuccinimidyl suberate (DSS), Song et al. (2016) mapped the
noncovalent interactions among 20S proteasome subunits in breast cancer cells21. Using a disuccinimidyl sulfoxide-based (DSSO) cross-linking and mass spectrometry platform, Wang et al.
(2017) mapped the interactions of Ecm29 within itself and with proteasome subunits and determined the architecture of the Ecm29-proteasome complex with integrative structure modeling23.
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Thus, HD exchange and XL-MS chemical crosslinking approaches can potentially identify and
structurally characterize the oligomer binding site on the proteasome. The potential druggability
of the oligomer-proteasome interaction can be assessed by analysis of the geometrical parameters and residue properties of the binding site11.
II. Proteasome gate activation by synthetic molecules
Study 2 characterized the mechanism of HbYX induced proteasome gate opening and identified
HbYX-based di-peptides as proteasome gate-activators. Notably, we developed a novel HbYX
dipeptide, ZYA (Figure 2). ZYA promotes proteasome gate opening and rescues proteasome activity from oligomer-mediated impairment, supporting the HbYX mechanism as a potential drug
target to restore proteasome activity in neurodegenerative diseases. These data provide a mechanistic

framework

to

develop

20S

small molecules directly activate
the proteasome gate, thereby in-

+

creasing proteasome activity and
protein degradation.

Figure 2. Activation of the proteasome gate with ZYA.

II.A. Mechanism of HbYX-motif proteasome gate opening
Detailed knowledge of the HbYX gate mechanism is essential for the rational design of gateactivating molecules. The first proteasome gating studies identified the mechanism of proteasomal ATPase-induced gate opening in the 20S by studying the archaeal 20S-PAN ATPase
(archaeal homolog of 19S ATPases) complex. The Goldberg Lab and colleagues demonstrated
that docking of the PAN ATPases’ C-termini (containing the conserved HbYX motif) in to the 20S
proteasome α-ring opens the 20S gate by a “key-in-a-lock” mechanism24–26. Furthermore, sevenresidue or longer peptides from PAN’s C-terminus containing the HbYX motif can by themselves
cause a rotation of the α-subunits to induce gate opening26. The process of 19S-20S complex
formation and gate opening is much more complex than PAN-20S interactions, due to the
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presence of six different 19S ATPases with distinct C-termini and seven distinct α-intersubunit
pockets in the eukaryotic 20S proteasomes. Nonetheless, the HbYX motif “key-in-a-lock” mechanism appeared to be conserved from archaea to mammalian proteasomes as gate opening could
be induced by seven-residue peptides from the 19S ATPase subunits C-termini (Rpt2 and Rpt5,
containing the HbYX motif)25.
Recent single-particle cryo-electron microscopy (cryo-EM) studies of yeast and human 26S proteasomes have revealed a complex mechanism for the 19S ATPase hydrolysis cycle, gate opening, substrate unfolding and translocation into the 20S core28-34. These studies have presented
structures of multiple 26S conformational states during the ATP hydrolysis cycle and substrate
processing, the majority of which have a closed 20S gate. Several structures show 19S ATPase
C-termini containing the HbYX motif (Rpt 5 and 3, plus Rpt 2 in some conformational states)
docked into α-intersubunit pockets in the absence of gate-opening. These data have been interested as evidence that the HbYX motif alone does not induce gate opening in eukaryotic proteasomes.
It is worth noting that cryo-EM analysis pf the 26S proteasome is not without experimental uncertainty. Single-particle EM depends on the computational averaging of thousands of images of
identical particles27. Since the 26S proteasome adopts many different conformations during the
ATP hydrolysis cycle, more homogeneous subsets of 26 conformations are generated using 2D
and 3D classification procedures prior to computational averaging of the particle subset. Nonetheless, the resultant 26S molecular structure is still derived from the averaged density of 10,000
to > 200,000 26S particles28. Averaging a subset of proteasome particles can obscure open-gated
proteasomes if they are a minority within the subset. Although one or more 19S ATPase C-termini
containing the HbYX motif are docked into α-intersubunit pockets in several closed-gate 26S
structures, the local resolution is >3.5Å28–34 which doesn’t allow identification of specific side chain
interactions between the HbYX motif and the α-subunits. Therefore, the precise position of the
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HbYX motif in the α-intersubunit pocket and whether or not it is interacting with the conserved
residues required for gate opening (e.g. K66, P16) cannot be determined at these resolutions.
Conflicting evidence between the biochemical and structural studies described above casts doubt
on the utility of using HbYX derived molecules to activate mammalian proteasomes. Study 2 fills
this knowledge gap by defining the mechanism of HbYX motif gate activation at the molecular
level (i.e. displacement of P16 backbone outward from the 20S pore axis resulting from a hydrogen bond with the HbYX tyrosine hydroxyl group) and designed a synthetic dipeptide (ZYA) capable of activating the mammalian 20S gate and increasing protein degradation. ZYA is an effective gate activator (increasing activity over 50-fold) but has relatively low affinity for the proteasome (~1 mM Kd). Future structure-activity relationship (SAR) models of ZYA-derivatives combined with an iterative process of design and screening can potentially generate new gate-

activating compounds with improved potency and drug-like characteristics.
III. Future Perspectives
Impaired proteasome function has been implicated in the development of many neurodegenerative diseases5–9, and increasing proteasome activity has been recognized as a promising new
approach to delay the onset or ameliorate the symptoms of neurodegenerative and other protein
misfolding disorders35–37. Taken together, Study 1 and Study 2 identify a mechanism of proteasome impairment by disease-associated oligomers and demonstrate that proteasome gateactivating molecules can increase protein degradation and overcome neurodegenerative-oligomer impairment. However, our studies were performed in vitro with purified proteasomes, and
several important questions remain unanswered.
III.A. In vivo proteasome activation
While cultured cells, drosophila, and nematodes respond favorably to increased proteasome activity (e.g. via ectopic proteasome delivery, proteasome subunit overexpression, genetic open-
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gate mutations)14,17,38–40, these model systems are short-lived compared to humans and cannot
recapitulate all aspects of human neurogenerative disease. Notably, pathological changes at molecular and cellular levels in human patients precedes the clinical onset by several years. In fact,
neuron loss is apparent at the onset of neurological symptoms and that neuronal dysfunction and
abnormal protein deposited in the brain are already detectable in asymptomatic carriers of a gene
mutation of familial neurodegenerative disease. We do not know if pharmacologically activating
the proteasome in an organism with preexisting disease pathology can restore cellular proteostasis and if this is enough to have a positive impact on neural function and human health.
III.B. Crosstalk between the proteasome and autophagy
Autophagy is responsible for nonspecific, bulk degradation of cytoplasmic components. Recent
work has also revealed specific, autophagic degradation of polyubiquitinated proteins and aggregates41,42, and dynamic activity regulation between the UPS and autophagy43–45. Even though
several biochemical mechanisms underlying crosstalk between them have been suggested 45,46,
less is known about the effect of enhanced proteasome activity on autophagic flux. Studies have
shown that increased proteasome activity (achieved with hyperactive α3ΔN proteasomes or by
pharmacological inhibition of USP14) inhibit autophagy flux at the autophagosome–lysosome fusion step14,47. The mechanism of autophagy inhibition appears to involve enhanced proteasomal
degradation of the autophagosome–lysosome fusion protein, UV radiation resistance-associated
gene (UVRAG)14,47, p53, and p6214. Consequently, although proteasome activation improved the
clearance of aggregation-prone proteins and reduced the amount of oligomers14,47, these conditions also increased the formation of inclusion bodies from nonproteasomal substrates (such as
huntingtin with expanded polyglutamine repeats)47 and the number of GFP-LC3 puncta (a marker
of autophagosomal structures)14. In contrast, other studies have shown that proteasome activation through genetic and pharmacological inhibition of USP14 corrected an in vivo model of
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impaired mitophagy48 and increased autophagic flux49,50, likely through suppression of K63 ubiquitination of Beclin150.
Taken together, these observations highlight the fact that while a strategy enhancing proteasome
activity may be beneficial in the treatment of neurodegenerative disease, it may have caveats
originating from crosstalk mechanisms between the UPS and autophagy. Thus, future efforts are
needed to address the effect of proteasome activation on autophagy regulatory mechanisms and
identify the molecular link between proteasome activity and autophagic flux.
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